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ABSTRACT
BACKGROUND: There has been an increase in the diagnosis of depression and
the use of antidepressants, especially in women of childbearing age, in the past decade.
This has drawn attention to the potential impact of depression and antidepressants on
pregnancy and fetal development.
OBJECTIVE: (i) To determine the impact of prenatal exposure to antidepressant
on the risk of adverse birth outcomes. (ii) To assess the effect of type of antidepressants
on the risk of adverse birth outcomes using selective serotonin reuptake inhibitors as the
referent group. (iii) To assess the effect of duration and time of prenatal exposure to
antidepressants on the risk of adverse birth outcomes.
METHODS: The study was conducted using a population-based cohort including
all singletons deliveries in years 2008 to 2014 in SC Medicaid population. Information on
antidepressant medication and diagnosis of depression and birth outcomes were obtained
from South Carolina Medicaid database and birth certificates. The exposed group
comprised children of mothers who had a diagnosis of depression and used
antidepressants at any time during their pregnancy. The reference group comprised
children of mothers who had a diagnosis of depression but did not use any
antidepressants during pregnancy. We estimated the association using Logistic
Regression and Marginal Structural Models.
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RESULTS: Approximately 107, 683 women had a diagnosis of depression in the SC
Medicaid population. After applying the study inclusion and exclusion criteria, we got the
study sample of 4,450 women. And approximately 36% women received antidepressants
during pregnancy. (i) In our study we found that using logistic regression the odds of
having preterm delivery were 1.58 (95%CI: 1.19 – 2.10) in those who received an
antidepressant during pregnancy as compared to those who did not receive any
antidepressants at any time during the pregnancy. Using marginal structural models, the
odds of preterm delivery were 1.72 times (95% CI: 1.63 – 1.79) in the group that received
antidepressants during pregnancy as compared to those who did not. Using logistic
regression it was estimated that antidepressant use during pregnancy was associated with
higher odds of the infant having low birth weight/being small for gestational age, OR =
1.57 (95% CI: 1.42 – 2.76) and/or NICU admissions, OR: 1.45 (95%CI 1.28 – 2.26).
Marginal structural models showed that the prenatal exposure to antidepressants
increased the odd of having low birth weight/small for gestational age 1.63 times
(95%CI: 1.53 – 1.73) and the odds of having a NICU admission by 1.66 times (95% CI:
1.58 – 1.73). (ii) Upon comparing the different classes of antidepressants to SSRIs we
found that the risk of adverse birth outcomes was not significantly different between the
different types of antidepressants. Only TCAs had a statistically lower risk of NICU
admissions as compared to SSRIs. Using marginal structural models we found that the
risk of NICU admissions was 0.85 times (95% CI: 0.65 – 0.97) lower in TCAs as
compared to SSRIs. (iii) Exposure to antidepressants in all three trimesters was
associated with the risk of adverse birth outcomes. Although the duration of exposure that
is the number of days for which the antidepressant was prescribed in each trimester was
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not associated with the risk of adverse birth outcomes. Conducting additional analysis we
found that the risk of low birth weight/small for gestational age and NICU admissions
was higher with exposure in the third and second trimester as compared to the first
trimester.
CONCLUSION: In conclusion we found that prenatal exposure to antidepressants
is significantly associated with a higher risk of adverse birth outcomes such as preterm
delivery, low birth weight/small for gestational age, and NICU admissions, irrespective
of the type of antidepressant prescribed and duration and trimester of exposure.
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CHAPTER 1
INTRODUCTION
1.1 DEPRESSION
Depression is a mood disorder that causes a persistent feeling of sadness and loss
of interest1. Symptoms of depression can be categorized in three groups—mood,
cognitive, and physical symptoms. Mood symptoms include depressed, sad, or irritable
mood; loss of interest in usual activities; inability to experience pleasure; feelings of guilt
or worthlessness; and thoughts of death or suicide1. Cognitive symptoms include inability
to concentrate and difficulty in making decisions1. Physical symptoms include fatigue,
lack of energy, feeling either restless or slow, and changes in sleep, appetite, and activity
levels1. World Health Organization (WHO) recognizes depression as a worldwide
epidemic, with 5 percent of the global population suffering from the condition2.
According to Centers for Disease Control and Prevention (CDC) depression is one of the
leading causes of disability in the United States3. Depression statistics published by the
CDC show that about 9 percent of adult Americans have feelings of hopelessness,
despondency, and/or guilt that generate a diagnosis of depression3. At any given time,
about 3 percent of adults have major depression, also known as major depressive
disorder, a long-lasting and severe form of depression3. The average age for a person to
be diagnosed with depression is 323. The prevalence of depression is comparatively lower
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(6.8%) among those age 65 and older3. Prevalence of depression is also affected by race,
according to the CDC, African-Americans have the highest rate of current depression
(12.8 percent), followed by Hispanics (11.4 percent), and whites (7.9 percent) 3. A report
published by National Institute of Mental Health (NIMH) states that women are 70
percent more likely than men to experience depression during the course of their
lifetimes4. One in four women suffer symptoms of depression at some point during their
life5. Women of childbearing age are at a higher risk for depression2-4. According to the
American Congress of Obstetricians and Gynecologists (ACOG) between 14 – 23% of
women struggle with symptoms of depression during pregnancy6.
The personal and societal costs of depression are significant. They include higher
rates of death, serious complications for chronic disease patients, significantly higher
health care costs for employers, added family caregiver burden and associated substance
abuse problems. Studies show that depression is associated with higher mortality rates in
all age groups. In the United States, the total economic burden of depression was
estimated to be US$ 83.1 billion in 2000, of which US$ 26.1 billion (31%) were direct
medical costs, US$ 5.4 billion (7%) were suicide-related mortality costs and US$ 51.5
billion (62%) were workplace costs6. Since then the societal cost of depression has
increased to $118 billion in 20133-4. According to WHO, major depression carries the
heaviest burden of disability among mental and behavioral disorders. It accounts for 3.7
percent of all U.S. disability-adjusted life years (DALYs); and, 8.3 percent of all U.S.
years lived with disability (YLDs) 2, 4.
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1.2 ANTIDEPRESSANTS

The most common treatments for depression are medication and psychotherapy.
Based on their mechanism of action antidepressants are classified into the following
therapeutic categories –


Selective serotonin reuptake inhibitors (SSRIs)



Serotonin-norepinephrine reuptake inhibitors (SNRIs)



Tricyclic antidepressants (TCAs)



Monoamine oxidase inhibitors (MAOIs)



Atypical agents

Antidepressants were one of the 10 most popular type of drug dispensed in US in
2013, with $13.7 billion in sales. According to the National Centre for Health Statistics
(NCHS) antidepressants were the third most common prescription drugs taken by
Americans of all ages in 2005–2008 and the most frequently used by persons aged 18–44
years7. More than 60% of Americans taking antidepressant medication have taken it for 2
years or longer, with 14% having taken the medication for 10 years or more7. The CDC
and NCHS also report that females are two and half times as likely to take antidepressant
medication as males2, 7.
1.3 DEPRESSION AND ANTIDEPRESSANTS IN PREGNANT WOMEN

In 2005 the prevalence of major depression in pregnant women ranged from 3.1%
– 4.9%, and that of major or minor depressive episodes ranged from 8.5% – 11% (minor
3

depression here refers to sub-threshold depression or depressive disorder not otherwise
specified) 8. Since 2005 the prevalence of depression has increased9. According to the
American Congress of Obstetrics and Gynecologists the prevalence of depressive
disorders (major and minor depression) in pregnant women ranges from 14% to 23%9-11.
The increase in prevalence of depression has translated to an increase in the use of
antidepressants. Over the past decade the proportion of pregnancies with antidepressant
use has increased from 5.7% of pregnancies to 13.4% of pregnancies and is projected to
increase further 6, 12. Prevalence of antidepressant prescription is lower during pregnancy
as compared to pre-pregnancy and post-partum13. The use of antidepressants during
pregnancy is mostly during the first trimester13-14. Studies show that there is a reduction
in the use of antidepressants from the first trimester (3.7%) to the second (1.6%) to the
third (1.1%) 12-14.
1.3.1 South Carolina Medicaid Population
According to CDC the current rate of depression in South Carolina is 9.6%3.
According to a report published by the University of South Carolina in the year 2009 a
total of 31,542 female Medicaid recipients had paid claims associated with a primary
diagnosis of depression or 3.4 percent of the total Medicaid recipient population15. Total
medical expenditures for this population were $390,062,477 accounting for 9.03 percent
of the state Medicaid expenditures15. Another report by the South Carolina Department
of Health and Environment Control (DHEC) in the years 2004-2009 approximately 40%
of pregnant of women had a diagnosis of depression in South Carolina Medicaid
population16. Nearly 42% are prescribed antidepressants during pregnancy16.
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1.4 IMPACT OF MATERNAL DEPRESSION AND PRENATAL EXPOSURE TO
ANTIDEPRESSANTS ON BIRTH OUTCOMES

Depression during pregnancy has received little attention from healthcare
professionals and researchers as compared to postpartum mental health of women16,
mainly due to the belief that pregnancy can have a protective effect against depression 17.
This has resulted in limited knowledge about depression during pregnancy and its impact
on fetal growth and development17. However, there has been an increase in the diagnosis
of depression and the use of antidepressants18, especially in women of childbearing age1820

, in the past decade. This has drawn attention to the potential impact of depression and

antidepressants on pregnancy and fetal development.
Due to the unusual risk-benefit situation, healthcare providers avoid prescribing
drugs during pregnancy11. However, studies show that maternal depression can have an
impact on the pregnancy and fetus21. Untreated depression has been found to be
associated with preterm delivery, low birth weight and small for gestational age22-23.
Although no studies have explored the direct association between maternal depression
and structural malformations, some researchers have found that maternal depression is
associated with poor fetal and head growth23, providing evidence that depression may be
associated with malformations as well.
A number of studies have explored the association between prenatal exposure to
antidepressants and poor birth outcomes. Many of the studies show that exposure to
antidepressants during gestation is associated with preterm delivery, low birth weight,
small for gestational age, and structural malformations24-26. Discontinuing the prescribed
5

antidepressants can lead to relapse. Approximately 68% of women who stopped taking
antidepressants relapsed during pregnancy making the fetus susceptible to the harmful
effects of depression27.
Maternal depression and antidepressants both have been associated with adverse
birth outcomes such as pre-term delivery, low birth weight/ small for gestational age and
structural malformations22-26, which makes it difficult to study the independent
association between antidepressants and adverse birth outcomes.
1.5 BIOLOGICAL PLAUSIBILITY
1.5.1 Maternal Depression

Depression can have a direct effect on the development of fetus and maintenance
of pregnancy11. It has been associated mainly with preterm delivery, low birth weight,
and spontaneous abortion11, 14, 28. Very few studies have looked at the impact of maternal
depression on structural malformations. Although the exact pathology of the phenomenon
has not been identified there are two widely accepted theories. The first theory proposes
that the neurobiological substrates of depression such as glucocorticoids have the ability
to cross the placenta and can result in hormonal shifts and interactions, which in turn are
detrimental to development of fetus and maintenance of pregnancy29. The second theory
proposes that the fetus may be affected due to the altered fetal environment caused by
maternal depression and stress28, 29. Levels of hormones such as gonadal, estrogens and
progesterone increase during pregnancy. Production of other hormones such as placental
corticotropin-releasing hormone (CRH), cortisol, human chorionic gonadotropin,
prolactin, b-endorphin, and thyroid hormone-binding globulin also increases during
pregnancy. The production of these hormones is controlled by complex interactions and
6

feedback systems that exist between the hypothalamicpituitary-ovarian (HPO) axis and
the hypothalamicpituitary-adrenal (HPA) axis. The HPA axis plays a vital role, as it’s
functioning and release of hormones is influenced by pregnancy and by stress29. Studies
show that women’s cortisol levels are higher when they experience negative moods30;
providing evidence to support a link between the HPA axis and psychological distress
during pregnancy29, 30. Changes in the HPA axis and subsequent changes in cortisol levels
resulting from stress and/or depression can alter the fetal environment.
Depression can also have an indirect impact on the fetus through poor health
behaviors, such as poor eating and poor weight gain, and poor sleep and subsequent use
of over the-counter medication, alcohol, tobacco, or caffeine26.
1.5.2 Antidepressants

The potential impact of maternal depression on the development of fetus and
maintenance of pregnancy has highlighted the risks of untreated depression; this in turn
has contributed to an increased use of antidepressants during pregnancy. Unfortunately
prenatal exposure to antidepressants can also result in adverse birth outcomes.
Antidepressants can enter the fetal circulation by crossing the placenta31. The fetus may
also be exposed to the drug through amniotic fluid, which means exposure to even greater
amounts than usually considered

31

. Although the biological mechanism is still unclear

this exposure has been associated with adverse birth outcomes such as small for
gestational

age/low

birth

weight

32,33

,

malformations37-38.
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preterm

delivery34-36,

and

structural

1.6 ADVERSE BIRTH OUTCOMES

1.6.1 Preterm Delivery

World Health Organization defines preterm delivery as delivery before 37 weeks
of gestation are completed39. Every year, an estimated 15 million babies are born preterm.
In 2013 it preterm birth complications were the leading cause of death among children
under 5 years of age, responsible for nearly 1 million deaths39. A report published by
National Center for Health Statistics stated that the rate of preterm birth in the US is
12.7%

40

. Preterm-related is the leading cause of infant deaths accounting for almost

35%41. Preterm birth is also a leading cause of long-term neurological disabilities in
children. Preterm birth costs the U.S. health care system more than $26 billion in 200541.
The preterm birth rate varies by race and ethnicity42. In 2012, 16.53 percent of babies
born to non-Hispanic Black women were born preterm, compared to 10.29 percent of
babies born to non-Hispanic White women, and 10.15 percent of babies born to
Asian/Pacific Islander women. Among babies born to Hispanic women, 11.58 percent
were born preterm, while the same was true for 13.25 percent of babies born to American
Indian/Alaska Native women

42-43

. Rates of preterm birth vary in different regions of the

United States and among states44. Preterm birth rates are highest in Mississippi, Alabama,
Louisiana, Kentucky, South Carolina, and the District of Columbia and lowest in New
Hampshire, Vermont, Oregon, Minnesota, Alaska, Connecticut, and Idaho45. According
to the March of Dimes the rate of preterm delivery in South Carolina was 13.8%43.
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There are several factors associated with the risk of preterm delivery. Women
who have delivered preterm before, or who have experienced preterm labor before, are
considered to be at high risk for preterm labor and birth46. Multiple gestations or the use
of assisted reproductive technology is associated with a higher risk of preterm labor and
birth. One study showed that more than 50% of twin births occurred preterm, compared
with only 10% of births of single infants47. Certain medical conditions such as urinary
tract infection, diabetes, sexually transmitted diseases have also been associated with
preterm delivery48.

Preterm labor and birth occur more often among certain racial and

ethnic groups. Infants of African American mothers are 50% more likely to be born
preterm than are infants of white mothers49. Age is also associated with the risk of
preterm delivery. Women younger than age 18 are more likely to have a preterm
delivery47. Women older than age 35 are also at risk of having preterm infants because
they are more likely to have other conditions (such as high blood pressure and diabetes)
that can cause complications requiring preterm delivery49. Other risk factors associated
with preterm delivery are certain lifestyle and environmental factors, which include late
or no health care during pregnancy, smoking, drinking alcohol, using illegal drugs,
domestic violence, including physical, sexual, or emotional abuse, lack of social support,
stress, long working hours with long periods of standing and exposure to certain
environmental pollutants 48.

Studies show that stress and depression are associated with a higher risk of
preterm delivery 48-50. Some studies also show that the prevalence of preterm delivery is
higher in mothers who take antidepressants during pregnancy as compared to those who
do not24-26,

33-34

. Although other studies have concluded that there is no significant
9

association between exposure to antidepressants during gestation and the odds of having
preterm delivery35-38.

1.6.2 Low Birth Weight/ Small for Gestational Age

Low birth weight (LBW) infant is defined as the one whose weight is less than
2,500 g (5 pounds 8 ounces) regardless of gestational age
weight in the US is about 8%

40

40

. Prevalence of low birth

. Small for gestational age (SGA) babies are those who

are smaller in size than normal for the gestational age, most commonly defined as a
weight below the 10th percentile for the gestational age 51-52. According to the Centers for
Disease Control and Prevention the prevalence of small for gestational age has been on
the rise since 2005 and is currently about 11% 53. The LBW/SGA rate in South Carolina
has risen from 9.3% to 10.1%, from 1993 to 2013

54-55

. The risk of LBW/SGA is

significantly greater among African Americans, whose rate is 14.6%, compared with
7.6% of White or Hispanic babies54-55. The excess cost to the medical system of
supporting a low or very LBW/SGA baby is high. An LBW/SGA baby incurs an average
of $16,500 in hospital costs and a very low birth weight baby an average of $95,000

54

.

The total medical cost of LBW/SGA babies in South Carolina is over $160 million per
year 55.
There are several risk factors associated with LBW/SGA. Preterm labor is often a
cause of LBW/SGA. Certain health conditions such high blood pressure, diabetes and
infections may lead to LBW/SGA46. Women who don’t gain enough weight during
pregnancy are more likely to have a LBW/SGA baby than women who gain the right
amount of weight. Smoking, drinking alcohol, and illicit drug use has also been
10

associated with LBW/SGA. Pregnant women who smoke are nearly twice as likely to
have a LBW/SGA baby as women who don’t smoke49. Women younger than 17 years or
older than 35 years are more likely to give birth to a LBW/SGA baby49. And
race/ethnicity is a risk factor as well. In the United States, African-American women are
more likely than others to have a LBW/SGA baby. Approximately 13% AfricanAmerican babies are born with LBW/SGA each year. 8.4 percent of Asian babies, 7.6
percent of Native American babies, and about 7 percent of Hispanic and Non-Hispanic
White babies are born with LBW/SGA53-55.
Studies suggest that depression is an important risk factor for LBW/SGA56.
Women with depression during pregnancy are at increased risk for LBW/SGA57. These
studies stress the need for treating antenatal depression to reduce the risk of LBW/SGA.
However, literature is conflicted regarding the association between gestational exposure
to antidepressants and low birth weight/small for gestational age. Some studies show that
prenatal exposure to antidepressants is associated with a higher risk of LBW/SGA33-34
whereas other studies show that the association is minimal to none35-38.
1.6.3 NICU Admissions
Preterm and/or low birth weight infants need special care, including additional
attention to breastfeeding and breast-milk feeding and to keeping them warm at home and
in health facilities. Those with preterm birth complications, including respiratory
problems, need appropriate treatment in hospitals. A neonatal intensive-care unit (NICU),
also known as an intensive care nursery (ICN), is an intensive-care unit specializing in
the care of ill or premature newborn infants58-59. Newborns, including those who are full
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term and of normal birth weight, are admitted to a NICU for many types of illness. Every
newborn admitted to a NICU experiences the benefits of such highly specialized care and
is exposed to the associated risks and high costs. Despite the published research into
interventions or patterns of care for specific populations, there has been no published
study examining NICU admission rates across the entire range of newborn morbidity
because the necessary data have, until recently, been unavailable or difficult to access5859

.
Neonatal intensive care (NICU) admissions increased from 2007 to 2012. In

2012, there were 43.0 NICU admissions per 1000 normal-birth-weight infants (25003999 g), while the admission rate for very low-birth-weight infants (<1500 g) was 844.1
per 1000 live births60. Overall, admission rates during the 6-year study period increased
from 64.0 to 77.9 per 1000 live births (relative rate, 1.22; 95% CI, 1.21-1.22 [P < .001]).
Admission rates increased for all birth weight categories. Trends in relative rates adjusted
for maternal and newborn characteristics showed a similar 23% increase (95% CI, 1.221.23 [P < .001]). During the study period, newborns admitted to a NICU were larger and
less premature, although no consistent trend was seen in weight for gestational age or the
use of assisted ventilation60-61.

Maternal depression and antidepressants have been associated with NICU
admissions. Studies show that stress and depression are associated with a higher risk of
NICU admissions 62-64. Some studies also show that the prevalence of NICU admissions
are higher in infants born to mothers who take antidepressants during pregnancy as
compared to those who do not64-70. Although other studies have concluded that there is no
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significant association between exposure to antidepressants during gestation and the odds
of NICU admissions71-74.

1.7 SUMMARY
A study conducted about perinatal depression in 2005 showed the prevalence of
major depression in pregnant women is in the range of 3.1%–4.9%, and that of major or
minor depressive episodes is in the range of 8.5%–11% (minor depression here refers to
sub-threshold depression or depressive disorder not otherwise specified)1-2. Since 2005
the prevalence of depression has increased. According to a recent report published by
American Congress of Obstetrics and Gynecologists (2014) the prevalence of depressive
disorders (major and minor depression) in pregnant women ranges from 14% to 23%3-4.
The prevalence for major depression has reached up to 7.5%2-4.

This increase in

prevalence of depression has directly translated to an increase in the use of
antidepressants. Over the past decade the proportion of pregnancies with antidepressant
use has increased from 5.7% to 13.4% and is projected to increase further

5-6

. Both

untreated depression and antidepressants have been associated with poor birth outcomes
such as preterm delivery, low birth weight and small for gestational age22-26. There are a
variety of other risk factors that have been associated with poor birth outcomes, these
include maternal smoking, poor prenatal care, drinking alcohol, using illegal drugs,
domestic violence etc48-50,61. Maternal depression, in addition to all these risk factors
makes assessing the impact of antidepressants alone on the fetus is a challenging 22-23.
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CHAPTER 2
LITERATURE REVIEW
Depression is a growing concern to healthcare professionals. It is a mental illness
that can be debilitating to patients and costly and challenging to treat. According to
Center of Disease Control and Prevention an estimated 1 in 10 US adults suffer from
depression1. Women are 70% more likely to suffer depression than men1. Depression has
become a common problem during and after pregnancy. Prevalence of depressive
disorders in pregnant women ranges from 14% to 23%2-3.
Depression if left untreated during pregnancy can negatively impact the mother
and fetus/child. The suffering mothers are most likely to experience inadequate weight
gain during pregnancy4, abuse substances5 and be at an increased risk of preeclampsia6-8.
Untreated depression can also be associated with preterm delivery, increased risk for low
birth weight infants9-10, fetal distress, increased risk of neonatal intensive care unit
admissions and need for caesarian delivery10-12. Hence it is important to treat maternal
depression during pregnancy, although only 13% of the women diagnosed with
depression get treatment during pregnancy13. This might be related to the adverse
outcomes associated with the use of antidepressants during pregnancy. Studies show that
prenatal exposure to antidepressants is associated with preterm births, low birth
weight/small for gestational age, structural malformations and increased risk of
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admissions to the neonatal intensive care unit14-20, autism spectrum disorders and
other neurodevelopmental disorders22-23.
Over the past decade several studies have assessed the association between
prenatal exposure to antidepressants and adverse birth outcomes, although the results
have been inconsistent.
2.1 PRETERM BIRTH
A number of studies have examined the incidence of preterm birth in women
prescribed antidepressants during pregnancy. Most of these studies are observational
studies. In most of the studies researchers have looked at the prevalence of preterm birth
but in contrast, some studies looked at mean gestational age.
Simon et al (2002)26, Djulus et al (2006)27, Oberlander et al (2006)28, Kallen et al
(2004)29, Suri et al (2007)30, and Wisner et al (2009)31 have conducted studies that show
that the odds of having preterm delivery are higher when there is exposure to
antidepressants during gestation. On the other hand Sivojelezova et al (2004)32, Malm et
al (2005)33, Andersson et al (2004)34 and Yonkers et al (2009)35 have concluded that there
is no significant association between exposure to antidepressants during gestation and the
odds of having preterm delivery. Studies that have found an association between in utero
antidepressant exposure and gestational age typically show a small difference in mean
gestation duration of about a week or less

32-33,36

. The study conducted by Einarson et al

(2003)24 showed that the association is dependent on the duration of exposure; that longer
exposures are more likely to decrease gestational age36. All of these are prospective
cohort studies, involving different classes of antidepressants (SSRIs, Mirtazapine, TCA
and SNRI). Maschi et al (2008) revealed a correlation between preterm birth and chronic
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exposure to antidepressants but not with short term exposure57. All of these studies have
similar weaknesses, with no measures of actual drug exposure or controls for
confounders such as smoking and in particular the effects of underlying depression.
Some studies have tried to control for untreated maternal depression. Oberlander
et al (2006)36 examined 119 547 prescription records matched with hospital separation
records and found that SSRI-exposed babies had a higher rate of preterm birth than
babies exposed to depression alone (p < 0.01). A further study, by the same group, of
3500 cases found that increased length of drug exposure was related to higher risk of low
gestational age and low birth weight (Oberlander et al 2008)28. These studies are
weakened by the fact that hospital records may be unreliable and that the authors did not
correct for multiple comparisons. A small prospective study compared women with
depression alone and treatment with SSRIs and found a statistically significant higher
preterm birth rate in the exposed infants (14% exposed group, 0% depressed group)28. In
contrast, another small study did not detect any difference between treated and depressed
groups

32

. Wisner et al (2009) designed study a looked that looked at five overlapping

groups using a prospective design31. Patients were classified into those with no SSRI or
depression exposure, those with continuous or partial SSRI exposure and those with
continuous or partial depression exposure. Unlike most other studies, exposure was
confirmed with serum SSRI levels. The group with continuous SSRI exposure had a
significantly higher preterm delivery rate with a RR of 5.43 (95%CI 1.98-14.84). The
group with continuous depression also had a higher rate but this was no longer
statistically significant when controlled for maternal age and race, RR 3.7 (95%CI 0.9814.13). The partial SSRI and partial depression groups were no different from controls.
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Another study conducted by Simon et al (2002)26 evaluated the effects of prenatal
antidepressant exposure on adverse perinatal outcomes using a matched case control
study. The authors found that exposure to SSRIs were associated with a 0.9-week
decrease in mean gestational age and a 175-g decrease in mean birth weight. The odds of
having an adverse birth outcome was 4.3 (95%CI 1.5-12.2) times higher in the SSRI
exposed group as compared to the non-exposed group. They also looked at TCA
exposure and found that it was not significantly associated with adverse birth outcomes.
In this study the authors used a within a group-model health maintenance organization,
all infants

with apparent prenatal exposure to TCA or SSRI antidepressants were

frequency matched to an unexposed comparison group by year of birth, maternal age, and
mother’s lifetime use of antidepressant drugs and mental health care. A structured blind
review of mothers’ and infants’ medical records examined perinatal outcomes. The
authors also concluded that the effects on gestational age and birth weight were not
limited to the infants exposed late in pregnancy. A similar finding was reported by
Pastuszak et al. (1999) and Ericson et al. (18), while Chambers et al. (1996) found that
only third-trimester fluoxetine exposure was associated with a greater risk of premature
delivery. On the other hand Suri et al (2004)30 conducted a cohort study by following 90
women in a prospective, naturalistic design through pregnancy with monthly assessments
of symptoms of depression and anxiety using the Structured Clinical Interview for DSMIV mood module for depression, the Hamilton Depression Rating Scale, the Beck
Depression Inventory, and the Perceived Stress Scale. Participants included 49 women
with major depressive disorder who were treated with antidepressants during pregnancy
(group 1), 22 women with major depressive disorder who were either not treated with
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antidepressants or had limited exposure to them during pregnancy (group 2), and 19
healthy comparison subjects (group 3). The primary outcome variables were the infants'
gestational age at birth, birth weight, 1- and 5-minute Apgar scores, and admission to the
special care nursery. Groups 1, 2, and 3 differed significantly in gestational age at birth
(38.5 weeks, 39.4 weeks, 39.7 weeks, respectively), rates of preterm birth (14.3%, 0%,
5.3%, respectively), and rates of admission to the special care nursery (21%, 9%, 0%,
respectively). Birth weight and Apgar scores did not differ significantly between groups.
Mild to moderate depression during pregnancy did not affect outcome measures. They
concluded that prenatal antidepressant use was associated with lower gestational age at
birth and an increased risk of preterm birth but not with low birth weight or being small
for gestational age. This study is limited by its small sample size. The authors looked at
the impact of only one antidepressant that is Fluoxetine and did not account for the dose
of the drug.
A retrospective cohort study conducted by Pearson et al (2007)32 had a similar
conclusion that no evidence of major increases in risk of preterm birth or other adverse
neonatal outcomes following prenatal exposure to antidepressants, nor between SRIs and
TCAs. They compared the medical records of 84 pregnant women with major depressive
or anxiety disorders (DSM-IV criteria) who took antidepressants during pregnancy
(cases) versus a 2:1 age- and parity-matched control group of 168 unexposed women.
Women in the case group had sought psychiatric consultation regarding the use of
medication from the Perinatal and Reproductive Psychiatry Program at the Massachusetts
General Hospital between 1996 and 2000. There were no significant differences among
cases versus controls and their offspring, with respect to various neonatal and obstetrical
28

outcomes, including gestational age and weight, although 1-minute Apgar scores were
slightly lower in exposed infants. Admissions to the special care nursery were more
frequent, but briefer and based on relatively minor indications, among case newborns.
There were no significant differences in neonatal outcomes between exposures to
serotonin reuptake inhibitor (SRI) and tricyclic (TCA) antidepressants. Although the
authors of this study controlled for maternal depression they failed to mention the
trimester of exposure and doses. Also, the sample size of this study is not large enough to
give statistically significant results.
2.1.1 Summary
Preterm birth is a major clinical problem throughout the world. Numerous studies,
of varying size and quality, have examined the effects of antidepressant medication use
on pregnancy outcomes, including preterm birth. They differ in terms of the timing of the
antidepressant exposure during pregnancy and adjustment for potential confounding
variables, including lifestyle factors, co-morbidities, and the severity of the underlying
depression. Although substantial, the literature is limited by inconsistent results and the
lack of an appropriate control group. The majority of studies have used depressed women
who are not on antidepressants or women with no depression and no antidepressant
prescription as the control group. In both the cases the controls do not help clarify the
impact of antidepressants. Also most of the studies have examined prenatal exposure to
SSRIs, there is limited information about the other classes of antidepressants24. Another
concern with the current literature is inadequate controlling of confounding. A number of
studies have failed to control for confounders such as maternal smoking24-25, parity8,11,24,
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duration and time of exposure13,18,25 to antidepressants and most importantly maternal
depression24-25.
2.2 LOW BIRTH WEIGHT and SMALL FOR GESTATIONAL AGE
As with pre-term delivery the literature regarding the association between prenatal
exposure to antidepressants and risk of low birth weight/small for gestational age
(LBW/SGA) has conflicting results (Table 2). Studies conducted by Oberlander et al
(2006)20, Simon et al (2002)19, and Wen et al (2006)38 found an association between
gestational exposure to antidepressants and low birth weight/small for gestational age.
They found that prenatal exposure to antidepressants increased the odds of the infant
being low birth weight/ small for gestational age. Although the difference in the odds
ratio in the exposed and unexposed group was minimal, this could be a result of the small
sample size of these studies. Similar studies conducted by Djulus et al (2006)19,
Sivojelezova et al (2004)29, Chun-Fai-Chan et al (2005)39 concluded that there is no
association between gestational exposure to antidepressants and low birth weight/small
for gestational age.
A prospective cohort study conducted by Casper et al (2003) compared children
whose mothers were diagnosed with major depressive disorder in pregnancy and elected
not to take medication (n = 13) to children of depressed mothers treated with SSRIs (n =
31) in terms of birth outcomes. The prevalence of preterm birth in the exposed group was
found to be 3% as compared to 8% in the non-exposed group (p = 0.53). The mean birth
weight of the infants in the exposed group was only 50g lesser as compared to the nonexposed group (p =0.84). Although the authors mention that the healthy lifestyle of the
women in the study (eg, use of prenatal vitamins, no smoking, little alcohol use, and
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regular exercise) makes this sample different from that of other published pregnancy
outcome studies and might have contributed to the finding that antidepressant drugs did
not increase the risk of prematurity or low birth weight. Laine et al (2003) and Wisner et
al (2009) for confounders such as depression, smoking, maternal age or maternal weight,
and these showed no differences in birth weight in babies born to exposed or nonexposed mothers34,44. Although the relatively smaller sample size does not give the study
sufficient statistical power to detect the differences exposed and unexposed groups in all
of these studies.
A similar study conducted by Kallen et al (2004) used data of 997 infants (987
mothers) after maternal use of antidepressants based on prospectively recorded
information in antenatal care documents. The study concluded that prenatal exposure to
antidepressants increases the risk of LBW/SGA (OR 1.88 95%CI 1.28-2.26). Wen et al
(2006) conducted a retrospective cohort study of 972 pregnant women who had been
given at least 1 antidepressant prescription in the year before delivery and 3878 pregnant
women who did not any antidepressant and who were matched by the year of the infant's
birth, the type of institute at birth, and the mother's postal code from 1990 to 2000 in the
Canadian province of Saskatchewan. The study showed that the risks of low birth weight
(adjusted odds ratio, 1.58; 95% CI, 1.19, 2.11were increased in infants who were born to
mothers who had received antidepressants during pregnancy. A prospective case control
study conducted by Oberlander et al (2008)28 showed similar results. The authors used a
population-based maternal and neonatal health records that were linked to prenatal
maternal prescription records for an antidepressant medication (n=3500). After
controlling for maternal illness and duration of exposure, using propensity score
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matching the study found that longer prenatal exposure increased the risks of lower birth
weight (P<0.05).

On the other hand Casper et al (2003) conducted a prospective cohort study where
children whose mothers were diagnosed with major depressive disorder in pregnancy and
elected

not

to

take

medication

(n

=

13)

were

compared

with children of depressed mothers treated with SSRIs (n = 31) on birth outcomes. After
the analysis the authors concluded that prenatal exposure antidepressants had no
significant impact on the birth weight of the newborn. Suri et al (2004)30 followed sixtyfour outpatient women with an Axis I diagnosis of major depressive disorder or no
psychiatric history were followed in each trimester of pregnancy with administration of
the CES-D. A subset of the women with depression received treatment with fluoxetine
during pregnancy. Subjects with a CES-D score greater than 16 at any time point were
further assessed for the presence of an active major or minor depressive episode. The
study had analyzable data for 62 women. No significant differences were found in
outcome variables between those women with exposure to medication and/or prenatal
depressed mood and those women without a history of depression.

Another study

conducted by Djulus et al (2006)27 used a prospective cohort study with 2 comparison
groups: disease-matched pregnant women diagnosed with depression taking other
antidepressants and pregnant women exposed to non-teratogens. The primary outcome
was major malformations in neonates; secondary endpoints included spontaneous
abortions, therapeutic abortions, gestational age at birth, and mean birth weight. Women
were recruited from 5 teratogen information services in Toronto, Canada; Farmington,
Conn., U.S.A.; Jerusalem, Israel; Rome, Italy; Sydney, Australia; and from the Drug
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Safety Research Unit in Southampton, United Kingdom. Women were recruited into the
study from June 2002 to August 2005. The authors found no difference in the mean
weight of the infants in the exposed and unexposed groups.

2.2.1 Summary
A large number of studies have looked at the association between prenatal
exposure to antidepressants and an increased risk of being low birth weight/small for
gestational age. All of these studies are observational with varying study designs and
conflicting results. Although the impact of maternal depression and stress on fetal
development has been well documented32-35, many studies fail to control for maternal
depression in either design or analysis. In addition a number of studies have failed to
control for confounders such as maternal smoking24-25, parity8,11,24, duration and time of
exposure13,18,25 to antidepressants.
2.3 NICU ADMISSIONS
Several studies have analyzed the associate between neonatal outcomes and
antidepressant exposure during pregnancy. Most of these studies show some association
between gestational exposure to antidepressants and neonatal adaptation difficulties.
Neonatal adaptation is measured in various ways, from gross markers such as NICU
admission to more subtle evaluations such as behavioral observations, in different studies
making it difficult to draw general conclusions. Large database or registry studies have
variously suggested an increased 1.5 times increased risk of NICU admission with third
trimester exposure compared to first trimester exposure
respiratory distress and low
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, and increased risks of

APGAR scores 49.
The 2005 meta-analysis50 of prospective controlled trials included consideration
of 1066 mother – infant pairs and found a three-fold increased risk of SCN/NICU
admission. None of the trials in the meta-analysis included a depressed, non-drug-treated
group. Two subsequent studies do include such a group. Of these, Ferreira et al (2007)
found a significant (p < 0.001) increase in abnormal movements, tone and respiratory
symptoms in 76 infants exposed to SSRIs or venlafaxine in the third trimester51.
Sivojelezova et al (2005) found that 132 infants exposed to citalopram in pregnancy had a
four-fold increased incidence of NICU admission compared to matched infants exposed
to untreated maternal depression or controls32. Whereas two other controlled studies did
not find an association between antidepressant exposure and neonatal adaptation
difficulties. Of these Casper et al (2003) was limited by a small sample size. Maschi et al
(2008) on the other hand was a larger trial including 200 women treated with
antidepressants and 1200 controls. Although a major limitation of this study was that the
information was collected through an interview with the mothers, so data may not be
accurate and an underreporting of neonatal complications, especially of the mild ones, is
likely. Studies examining the neonatal effects of antenatal exposure to TCAs are limited
to case reports and case series. Several case reports describe an association between
gestational clomipramine48-49and imipramine50-52 exposures with signs of neonatal
adaptation difficulties. In a prospective case series53 of 18 pregnant women on TCAs
(predominantly imipramine), all nine with third trimester exposure had infants with
adaptation difficulties. With regard to the newer antidepressants, evidence is scant. Some
of the controlled trials include venlafaxine exposure54-56 and suggest similar neonatal
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adaptation difficulties to SSRIs. Mirtazapine features only in case reports57-58 and in one
controlled study56, with a suggestion of both respiratory and thermoregulatory problems.
One case report exists for duloxetine59 documenting neonatal adaptation symptoms.
2.3.1 Summary
The literature on association between prenatal exposure to antidepressants and an
increased risk of NICU admission is limited as compared to the evidence on preterm
delivery and low birth weight/small for gestational age. One reason for NICU admissions
are not considered an outcome of interest is because they lack specificity. NICU
admissions can sometimes be a result of poor birth outcomes like preterm delivery, small
for gestational age or structural malformations. Studies that have examined the
association between prenatal exposure to antidepressants and an increased risk of NICU
admission have also been observational with varying study designs and conflicting
results. These studies have failed to control for confounders such as maternal smoking2425

, parity8,11,24, duration and time of exposure13,18,25 to antidepressants and maternal

depression24-25.
2.4 GAPS IN THE LITERATURE
The current literature related to the risk of adverse birth outcomes following
prenatal exposure to antidepressants is dominated by information on SSRIs and to a
lesser extent, TCAs and venlafaxine. Many of the published reports have contradictory
results with regard to a possible association. These conflicting results are most probably
the result of differences in the study cohorts and variation in the power the power of the
study due to the sample size which plays a vital role in aiding to detect differences in rare
events. Registry studies have been helpful in the sense that they provide information on
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large numbers of participants, but they often rely on secondary data about prescriptions
being filled and cannot confirm that antidepressants were actually taken.
The main limitation of the existing literature are:
2.4.1 Lack of Controlling for Maternal Depression
Studies show that maternal depression can have an impact on the pregnancy and
fetus60. Untreated depression has been found to be associated with preterm delivery, low
birth weight and small for gestational age60-61. Depression can have a direct effect on the
development of fetus and maintenance of pregnancy63. It has been associated mainly with
preterm delivery, low birth weight, and NICU admissions64-66. A majority of the studies
in the currently literature do not control for maternal depression68-70.
2.4.2 Inadequate controlling for confounders
Several of the studies examining the impact of prenatal exposure to
antidepressants on adverse birth outcomes fail to control for confounders such as
smoking status, mother’s BMI, gestational diabetes, gestation hypertension, duration and
trimester of exposure to antidepressants etc68-70. Also majority of studies do not control
details about antidepressants such a duration and trimester of exposure.
2.4.3 Large focus on SSRIs
Since SSRIs are the most commonly prescribed antidepressants, a majority of the
studies focus on the impact of prenatal exposure to SSRIs alone on adverse birth
outcomes68-70. Although there is still information available about the impact of prenatal
exposure to TCAs, the information related to Atypical and SNRIs is scant33,45-47.
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2.4.4 Observational studies
All the studies conducted to examine the association between prenatal exposure to
antidepressants and risk of adverse birth outcomes have been observational. Several
standard methods have been used in this setting to estimate the association between
prenatal exposure to antidepressants and the risk of adverse birth outcomes33-35,68-70.
However, none of the methods can be used to establish causality. Ideally a randomized
controlled trial would be conducted to establish a causal association. Due to ethical
concerns we cannot randomize treatment in this study population.
2.5 SUMMARY
Literature on the association between prenatal exposure antidepressants and risk
of adverse birth outcomes though voluminous, is conflicting. Assessing the impact of
antidepressants on birth outcomes is a challenging task. It is vital to delineate the effects
of maternal depression, severity, other variables such as socioeconomic status, substance
use, and comorbidity medical and mental illnesses, from the effect of antidepressants on
birth outcomes3, 14-16. A systematic review of the relationship between antidepressant use
and poor birth outcomes conducted by Udechuku et al (2010) showed that most studies
do not have adequate power to detect rare events, and the large database analyses are
limited by the lack of appropriate controls47. Another systematic review of literature
concluded that although statistically significant associations between prenatal
antidepressant exposure and adverse birth outcomes are identified, the group differences
are small making it difficult to establish clinical significance48. Also most studies fail to
properly define the exposure, such as specific antidepressant used, indication, dosage,
time and duration of use, and number of antidepressants prescribed48.
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All the studies in the current literature are observational studies; ideally, for
estimation of the causal effects of prenatal exposure to antidepressants on adverse birth
outcome we would need to conduct a randomized controlled trial. A large sample of
women should be randomized to different treatment regimens at enrollment, with perfect
adherence ensured and no censoring; here, the assumption of no confounding would be
reasonable48. However, this is not possible in our study since withholding treatment
would be unethical. Hence establishing a causal association between prenatal exposure to
antidepressants and risk of adverse birth outcomes is not possible.
2.6 AIMS and HYPOTHESIS
Assessing the impact of antidepressants on the fetus is a challenging task as
potential confounding factors must be considered. It is vital to distinguish the effects of
maternal depression, socioeconomic status, maternal smoking, and comorbidities on birth
outcomes from the impact of antidepressants on those same outcomes

22-23

. Although

substantial, the literature is limited by inconsistent results and the lack of an appropriate
control group. The majority of studies have used depressed women who are not on
antidepressants or women with no depression and no antidepressant prescription. In both
cases the controls do not help clarify the impact of antidepressants. Also, while most of
the studies have examined prenatal exposure to SSRIs, there is limited information about
the other classes of antidepressants24. Another concern with the current literature is
inadequate controlling of confounding. A number of studies have failed to control
oconfounders such as maternal smoking 24-25, parity 8,11,24 , duration and time of exposure
13,18,25

to antidepressants and most importantly maternal depression

24-25

. The study

proposes to fill these gaps in the literature by testing the following hypothesis.
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Aim 1
To explore the association between prenatal exposure to antidepressants and risk
of adverse birth outcomes such as preterm delivery, low birth weight/small for gestational
age, and NICU admissions.
Study Hypothesis 1
Depressed women exposed to antidepressants during pregnancy have a higher risk
of adverse birth outcomes compared to women not exposed to antidepressants during
pregnancy.
Aim 2
To determine the association between types of antidepressant used on the risk of
adverse birth outcomes such as preterm delivery, low birth weight/small for gestational
age and NICU admissions.
Study Hypothesis 2
The risk of having adverse birth outcomes is higher in women prescribed
Selective Serotonin Reuptake Inhibitors compared to those depressed women who have
been prescribed other types of antidepressants.

Aim 3
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To determine the effect of trimester and duration of antidepressants on the risk of
adverse birth outcomes such as preterm delivery, low birth weight/small for gestational
age and NICU admissions.
Study Hypothesis 3
Depressed women who have late pregnancy exposure and for a longer duration
have greater risk of adverse birth outcomes compared to those with comparatively early
pregnancy exposure and shorter duration.
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CHAPTER 3
METHODS
3.1 DATA SOURCE
Data used in this study came from 2 administrative sources: 1) South Carolina
Medicaid claims 1, and 2) South Carolina registry of births from South Carolina
Department of Health and Environmental Control (DHEC) 2. The South Carolina
Revenue and Fiscal Affairs Office (RFA) created the de-identified dataset by merging
South Carolina Medicaid claims with the birth certificates.
3.1.1 South Carolina Medicaid Claims
Medicaid is South Carolina’s aid program through which the federal and state
governments provide insurance for eligible low-income adults, children, pregnant
women, elderly adults and people with disabilities 1-5. The database contained information
regarding an individual’s diagnosed medical conditions and the medications prescribed.
Medical conditions were coded using the International Classification of Diseases, 9th
revision, Clinical Modification (ICD-9-CM) codes. The pharmacy claims file of the
dataset contained information regarding the prescribed medications coded using National
Drug Codes (NDC), generic names and brand names

1-5

. To address medication use as a

depression treatment option in low-income pregnant women, we utilized South Carolina
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Medicaid claims data to identify a patient population that would most closely represent
our target population.
3.1.2 South Carolina Birth Registry
The South Carolina DHEC maintains the South Carolina Registry of Births
which is a database of all birth certificates issued in the state of South Carolina5. The
database contained the following information: birth weight, gestational age, weight for
gestational age, maternal height, maternal smoking, maternal alcohol use, maternal race,
maternal and paternal occupation, conditions during the pregnancy (ex. gestational
hypertension, anemia, eclampsia, gestational diabetes, uterine bleeding), birth
abnormalities or anomalies (ex. cleft palate, heart malformations), multiple births, NICU
admissions etc. Data from the birth certificates gave us information regarding the birth
outcomes such as pre-term delivery, low birth weight/small for gestational age, and
NICU admissions which helped us identify the cases accurately.
3.2 SELECTION OF STUDY POPULATION
The study population consisted of pregnant women who were enrolled in SC
Medicaid between the years 2008 – 2014 and fulfilled the following inclusion and
exclusion criteria.
3.2.1 Inclusion Criteria


Pregnant women of age between 18 - 50 years



Pregnancy ending with a delivery (live birth or stillbirth)



Diagnosis of depression concurrent with pregnancy



Enrolled for Medicaid continuously for the entire pregnancy (SC Medicaid
requires enrollment every month, and the database captures the claims filed
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during the months enrolled. Hence to ensure that use antidepressants during the
entire term of pregnancy is captured, it is important that the study participant be
continuously enrolled in SC Medicaid during that time.)
3.2.2 Exclusion Criteria


Multiple births



Illicit drug users (ICD 9 Code – 305.90)

If a woman had more than one pregnancy between 2008 and 2014, then each
pregnancy during which all eligibility criteria were fulfilled will be considered separately.
3.3 EXPOSURE
Pharmacy claims were used to identify all antidepressant prescriptions filled or
refilled during the pregnancy and before delivery. Study participants with no
antidepressant prescriptions during this period were considered unexposed. In this study
the following antidepressants were considered (brand name listed in parentheses):


Selective serotonin reuptake inhibitors (SSRIs) – Fluoxetine (Prozac),
Fluvoxamine (Luvox), Sertraline (Zoloft), Paroxetine (Paxil), Escitalopram
(Lexapro), and Citalopram (Celexa).



Tricyclic antidepressants (TCAs) – Amitriptyline (Elavil), Clomipramine
(Anafranil),

Desipramine

(Norpramin),

Doxepin

(Sinequan),

Imipramine

(Tofranil), Nortriptyline (Pamelor, Aventyl), Protriptyline (Vivactil), and
Trimipramine (Surmontil).


Atypical antidepressant – Bupropion (Wellbutrin), Duloxetine (Cymbalta),
Venlafaxine (Effexor), Mirtazapine (Remeron), and Trazodone (Desyrel).
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Serotonin-Norepinephrine Reuptake inhibitors (SNRIs) – Desvenlafaxine
(Pristiq), Duloxetine (Cymbalta), Venlafaxine (Effexor), Venlafaxine XR
(Effexor XR), Milnacipran (Savella), and Levomilnacipran (Fetzima)..

For study participants who are prescribed more than one class of antidepressant
during pregnancy both the classes were considered separately.
3.3.1 Duration of gestational exposure
The duration of gestational exposure was calculated as the number of days the mother
had been prescribed the antidepressant in each trimester. To estimate the duration of
exposure, we first estimated the date of conception based on the date of delivery and
gestational age. It is known that 10-13
Gestational Age = Date of Delivery – Date of Conception
Gestational age was obtained from the birth certificates, and date of delivery was
estimated using the dates corresponding to the delivery procedure codes. Using the date
of conception the time period for each trimester was calculated.
1st Trimester = Date of Conception + 90 days
2nd Trimester = Last date of 1st trimester + 90 days
3rd Trimester = Last date of 2nd trimester – Date of Delivery
Based on the dates of the trimester and the dates of exposure, number of days
antidepressant was prescribed during each trimester was calculated.
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In case there was a change in prescribed antidepressant the antidepressant prescribed
for the longer duration was the focus. If duration was similar for both antidepressants,
the first antidepressant prescribed was considered.
3.4 OUTCOMES
A study participant was considered to have the outcome if she had one or more of
the following adverse birth outcomes:
3.4.1 Preterm delivery
Preterm delivery was defined as a delivery before completion of 37 weeks of
gestation14-18. We got information on preterm delivery was obtained from birth
certificates.
3.4.2 Low birth weight
Low birth weight was defined as birth-weight less than 2,500 g (5 pounds 8
ounces) regardless of gestational age17, 18-23. We got information on preterm delivery was
obtained from birth certificates.
3.4.3 Small for gestational age
Small gestational age was defined as birth-weight below the 10th percentile of the
birth-weights for the gestational age in the given population19-23.

Indication that the

infant was small for gestation age was provided in the birth certificate file. All births
covered by SC Medicaid between years 2008-2014 served as the referent group19.
Although low birth weight and small for gestational age are not the ideal
measures for intrauterine growth, these are the two most commonly use measures in the
literature. Studies have found misclassification low birth weight as it is associated with
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preterm delivery and the magnitude and direction of misclassification differed by preterm
and full term birth. Also small for gestational age may not have been calculated
accurately as the estimation of gestational age is not always accurate24-25.
3.4.4 Neonatal Intensive Care Unit Admissions
NICU admission was identified from the birth certificates file. Information on
whether the infant had to be admitted to NICU right after birth was recorded in the birth
certificates 24-28.
3.5 COVARIATES AND POTENTIAL CONFOUNDERS
3.5.1 Mother’s Age
Mother’s age was obtained from birth certificates files. For analysis age was
categorized as:


18 – 28 years



29 – 38 years



≥ 39 years

3.5.2 Mother’s BMI
Pre-pregnancy BMI of the mother was reported in the birth certificate and was
categorized as:


Underweight (BMI < 18.5)



Normal weight (18.5 ≤ BMI > 25)



Overweight (25 ≤ BMI > 35)



Obese (BMI ≥ 35)
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3.5.3 Mother’s Education
Information regarding the education of the mother at the time of pregnancy was
obtained from the birth certificate. It was categorized as:


Less than high school



High school or GED



High school + some college



Bachelor’s degree or more

3.5.4 Kotelchuck Index/Prenatal Care

The Kotelchuck Index, also called the Adequacy of Prenatal Care Utilization
(APNCU) Index, is measure used to estimate adequacy of prenatal care a women
received during pregnancy19. It is calculated using – (i) the date prenatal care began
(initiation) and (ii) the number of prenatal visits between prenatal care initiation

and

delivery (received services). The Kotelchuck index classifies the adequacy of initiation as
follows: pregnancy months 1 and 2, months 3 and 4, months 5 and 6, and months 7 to 9,
with the underlying assumption that the earlier prenatal care begins the better. To classify
the adequacy of received services, the number of prenatal visits is compared to the
expected number of visits for the period between initiation and delivery date. The
expected number of visits is based on the American College of Obstetricians and
Gynecologists prenatal care standards for uncomplicated pregnancies, and is adjusted for
gestational age at date of care initiation, and for gestational age at delivery19.

Kotelchuck Index was categorized as follows:
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Inadequate (< 50%)



Intermediate (50% to 79%)



Adequate (80% to 109%)



Adequate Plus (≥ 110%)

3.5.5 Smoking Status
Mother’s smoking status was reported in the birth certificate file. Smoking status was
recorded for two time periods, (i) before pregnancy and (ii) during pregnancy.


During Pregnancy Smoking Status was categorized as:
o Yes – smoked during pregnancy
o No – did not smoke during pregnancy
o Unknown



Pre-pregnancy Smoking Status was categorized as:
o Yes – smoked before pregnancy
o No – did not smoke before pregnancy
o Unknown

Although the number of cigarettes smoked per day was not reported.
3.5.6 Diabetes
Information regarding the diagnosis of diabetes for the mother was given in the birth
certificate and the SC Medicaid medical claims file. The information on diabetes was
recorded as:


Yes – having a diagnosis of diabetes
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No – not having a diagnosis of diabetes

Diagnosis of diabetes was confirmed from the SC Medicaid medical files using ICD-9
codes (648.8).
3.5.7 Gestational Diabetes
Information regarding the diagnosis of gestational diabetes for the mother was
given in the birth certificate and the SC Medicaid medical claims file. The information on
gestational diabetes was recorders in the birth certificates file as:


Yes – having a diagnosis of gestational diabetes



No – not having a diagnosis of gestational diabetes

Diagnosis of gestational diabetes was confirmed from the SC Medicaid medical files
using ICD-9 codes (648.8).
3.5.8 Hypertension
Information regarding the diagnosis of hypertension for the mother was given in the
birth certificate and the SC Medicaid medical claims file.
The information on gestational diabetes was recorders in the birth certificates file as:


Yes – having a diagnosis of hypertension



No – not having a diagnosis of hypertension

Diagnosis of gestational diabetes was confirmed from the SC Medicaid medical files
using ICD-9 codes (648.8).
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3.5.9 Gestational Hypertension
Information regarding the diagnosis of gestational hypertension for the mother was
given in the birth certificate and the SC Medicaid medical claims file.
The information on gestational hypertension was recorders in the birth certificates file as:


Yes – having a diagnosis of gestational hypertension



No – not having a diagnosis of gestational hypertension

Diagnosis of gestational hypertension was confirmed from the SC Medicaid medical files
using ICD-9 codes (642).
3.5.10 Parity
Parity was defined as the number of pregnancies that end /delivered after 20 weeks
gestation. The number of fetuses in a pregnancy does not change the parity. Information
regarding parity was obtained from the birth certificates.
3.5.11 Number of Risk Factors
Total number of risk factors for poor birth outcomes present at the birth of an infant
were recorded in the birth certificate. The risk factors included poor prenatal care,
gestational diabetes, gestational hypertension, race, mother’s age, and mother’s BMI. As
the number of risk factors present increase so does the risk of adverse birth outcome.
3.5.12 Infant Sex
Infant’s gender at the time of birth was obtained from the birth certificate file,
specified as male and female.
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3.5.13 Race
As of 1990, Live Births are reported by race of mother instead of race of child19. Race
was categorized as follows in the birth certificate files:


Non-Hispanic White



Non-Hispanic Blacks



Hispanics



Others

3.5.13 Previous Poor Outcomes
The birth certificates contained information regarding experience of adverse birth
outcomes associated with a previous pregnancy. Adverse/poor birth outcomes included
the following: still born, pre-term delivery, low birth weight/small for gestational age,
structural malformations, NICU admissions, and abortions/miscarriages.

The

information was coded as follows:


Yes – had at least 1 of the adverse birth outcome in previous pregnancies



No – did not have any of the adverse birth outcomes in previous pregnancies

3.6 STATISTICAL ANALYSIS
Descriptive statistics (means, median, std. dev., percentages) was used to report
and describe the population. Hypothesis testing for categorical variables was conducted
using the Chi-square test. Hypothesis testing for continuous variables was conducted
using the t-test.
Two statistical methods were used to test the three study hypotheses –
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1. Logistic Regression
2. Marginal Structural Models (MSM)
There are several standard methods could be used to estimate the association between
prenatal exposure to antidepressants and the risk of adverse birth outcomes. However,
none of the methods can establish causality

14-28

. Ideally a randomized controlled trial

should be conducted to establish a causal association between gestational exposure to
antidepressants and an increased risk of adverse birth outcomes. Due to ethical concerns,
we cannot randomize treatment in the study population. Hence we used Marginal
Structural Models to estimate the causal effect of gestational exposure to antidepressants
on risk of adverse birth outcomes29-30. MSMs are a new class of causal models used in
epidemiology, the parameters of which are estimated through inverse-probability-of
treatment weighting. MSMs provide more robust estimates, with narrower confidence
intervals. In addition, a structural classification of bias distinguishes between biases
resulting from conditioning on common effects (“selection bias”) and those resulting
from the existence of common causes of exposure and outcome (“confounding”)30-34.
However the use of MSM in reproductive epidemiology/perinatal epidemiology has
been limited. We used two statistical methods because marginal structural models help
us delineate antidepressants from depression. Also, marginal structural models give us
the tool to statistically mimic a randomized control trial. We used logistic regression
like many previously published studies to make our results more comparable.
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3.6.1 Method 1 – Logistic Regression
A logistic regression was conducted to calculate the adjusted odds ratios along
with 95% confidence intervals using unexposed study population as the referent group.
Logit (Y) = β0 + β1L + β2A + β3x1 + β4x2
Y = adverse birth outcomes (preterm delivery, low birth weight/small for gestational age
and NICU admission)
A= use of antidepressants (SSRIs/TCAs/SNRIs/Atypicals)
L= maternal depression
x1

,

x2

,

x3,

…..=

covariates such as mother’s age, mother’s weight, parity and other

demographic variables etc
Backward selection was used to identify the variables significant at p-value <0.05.
In the analysis mother's age, mother's weight, mother's education, prenatal care
(kotelchuck index), smoking status’, parity, number of risk factors, infant sex, mother’s
race, year of birth, use of antidepressants, gestational diabetes, gestational hypertension,
and previous poor birth outcomes were found to be significant.
To ensure that the variables in the equation are not correlated with each other we
checked for multicollinearity, and found that number of risk factors was correlated to
gestational diabetes, gestational hypertension, and previous poor birth outcomes. Number
of risk factors included all risk factor associated with the three outcomes such as
infections, gestational diabetes, gestation hypertension, previous poor birth outcome etc.
Therefore we retained only the number of risk factors and removed other collinear
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variables. Multicollinearity can cause issues such as increase in variance of the
coefficient estimates and make the estimates very sensitive to minor changes in the
model, resulting in unstable and difficult to interpret coefficient estimates. (The
correlation matrix of the final set of predictor variables is presented in Appendix A)
3.6.2 Method 2 – Marginal Structural Models

The model was fitted in a two stage process30:
1. Each study participant’s probability of having their own treatment history was
calculated and used to derive inverse-probability-of-treatment weights (IPTW)
which were then standardized.
2. The treatment–outcome association was estimated in a regression model that w
weighted using the standardized IPTWs.
The Directed Acyclic Graph represents the association between maternal depression
(L), antidepressant (A) and adverse birth outcomes (Y)30-32.

Y represents the adverse birth outcomes (preterm delivery, low birth weight/ small for
gestational age, and structural malformations.)
A represents the exposure to antidepressants (dichotomous)
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Maternal depression L is a vector that predicts treatment A. ‘L’ accounts for all
variables such as age, race, parity, and other demographics. It also accounts for dose
and type of antidepressant.
We first created a pseudo-population using Inverse Probability (IP) weighting
where the arrow from the confounders L to the treatment A was removed. Here we
assume that the vector L has all the confounders that can open a backdoor path from
A to Y. Controlling for L will then eliminate all confounding in the pseudopopulation. That is, the association between A and Y in the pseudo-population
consistently estimates the causal effect of A on Y. The pseudo-population was created
by weighting each individual by the inverse of the conditional probability of receiving
the treatment, which are defined as
𝑊 𝐴 = 1/𝑓(𝐴|𝐿)

WA – Inverse probability weight
A – Exposure to antidepressants
L – Maternal Depression
The denominator ƒ (A|L) is the probability of getting the treatment conditional on the
measured confounders given by
𝑃𝑟[𝐴 = 1|𝐿]
The probability of getting treatment given the individual has depression was
[𝐴 = 1|𝐿] , and the probability that an individual does not get treatment given that she
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has depression can be given by 𝑃𝑟[𝐴 = 0|𝐿] . Although as treatment is dichotomous the
following holds true
𝑃𝑟[𝐴 = 0|𝐿] = 1 − 𝑃𝑟[𝐴 = 1|𝐿]
Weights were stabilized using the stabilizing factor ƒ (A). The mean of the stabilized
weights was 1, as the size of the pseudo population equals the size of the actual
population. The stabilized weight is given by
𝑆𝑊 𝐴 = 𝑓(𝐴)/𝑓(𝐴|𝐿)
SWA – Standardized inverse probability weight
The reason for using stabilized weights was that they are statistically superior to nonstabilized weights and will give comparatively narrower 95% confidence intervals. To
estimate 𝑃𝑟[𝐴 = 1|𝐿] for each strata of L we fitted a logistic regression model for the
probability of having depression with all the covariates. Next estimated the casual
difference 𝐸[𝑌 𝑎=1 ] − 𝐸[𝑌 𝑎=0 ] by fitting the mean model 𝐸[𝑌|𝐴] = 𝜃0 + 𝜃1 𝐴 with
̂ [𝐴 = 1]/
individuals weighted by their estimated stabilized IP weights given by 𝑃𝑟
̂ [𝐴 = 1|𝐿] for the depressed population and (1 − 𝑃𝑟
̂ [𝐴 = 1])/(1 − 𝑃𝑟
̂ [𝐴 = 1|𝐿]) for
𝑃𝑟
those who are not depressed. Using this counterfactual contrast we build the following
model
𝐸[𝑌 𝑎 ] = 𝛽0 + 𝛽1 𝑎
A = 1 – gestational exposure to antidepressants
A = 0 – no gestational exposure to antidepressants
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𝑌 𝑎=1 – Counterfactual outcome given everyone in the study population received
antidepressants
𝑌 𝑎=0 – Counterfactual outcome given nobody in the study population received
antidepressants
The notations used to describe the model have been borrowed from Robins et al30,
35-36

.
MSMs have been described and used by Hernan and Robins to estimate the causal

effect of zidovudine on the survival of human immunodeficiency virus-positive men
participating in the Multicenter AIDS Cohort Study38. The authors found MSMs to be a
better suited model for causal inference as compared to standard statistical models. The
assumptions of MSMs are the same as those in point exposure studies - accurate
information, and no misspecification of the model 37-38.
Although limited in number there are some perinatal epidemiology studies that
have used MSM. For example MSM has been used to establish the causal effect of iron
supplement use during pregnancy on odds of anemia at delivery in the presence of timedependent confounding

34

. Data from pregnant women enrolled in the Iron

Supplementation Study (Raleigh, North Carolina, 1997–1999) were used 34. The authors
concluded that if a data set with rich information on confounders is available, MSMs can
be

used

straightforwardly

to

make

robust

inferences

about

causal

effects

treatments/exposures in epidemiologic research 34.
All statistical analysis will be conducted using Statistical Analysis Software
version 9.4. Codes to conduct analysis using marginal structural models were taken from
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the Causal Inference Book. (Hernán MA, Robins JM (2016). Causal Inference. Boca
Raton: Chapman & Hall/CRC, forthcoming) 30.
3.6.3 Testing Study Hypothesis 1
The risk of adverse birth outcomes such as preterm delivery, low birth
weight/small for gestational age, and NICU admissions is higher in woman who received
antidepressants during pregnancy as compared to those who did not take
antidepressants.
A separate analysis was conducted for each adverse birth outcome – preterm
delivery, low birth weight/small for gestational age and NICU admissions, controlling for
all the available confounders. The analysis was conducted using logistic regression and
marginal structural models. Adjusted odds ratio along with 95% confidence intervals
were calculated for the association between antidepressant use during pregnancy and risk
of each adverse birth outcomes. Pregnant women with a diagnosis of depression who did
not have an antidepressant prescription were considered as the referent group. Mother’s
age, parity, mother’s weight, kotelchuck index, total number of risk factors, and
previously poor birth outcomes were found to be significant in the analysis.
3.6.4 Testing Study Hypothesis 2
The risk of adverse birth outcomes such as preterm delivery, low birth
weight/small for gestational age, and NICU admissions is higher in woman who received
Selective Serotonin Reuptake Inhibitors (SSRIs) antidepressants during pregnancy as
compared to other class of antidepressants such as Tricyclic Antidepressants (TCAs),
Selective Norepinephrine Reuptake Inhibitors (SNRIs).
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The second hypothesis was tested using the same methods. Each antidepressant type was
compared to the unexposed group using logistic regression and marginal structural
models. In addition we conducted another analysis using SSRIs as the reference group to
compare the risk between different classes of antidepressants. Adjusted odds ratios along
with 95% confidence intervals were calculated for the association between type of
antidepressant use during pregnancy and risk of each adverse birth outcomes. Mother’s
age, parity, mother’s weight, mother’s education, kotelchuck index, total number of risk
factors, and previously poor birth outcomes were found to be significant in the analysis.
3.6.4 Testing Study Hypothesis 3
Depressed women who have antidepressants during the first trimester of
pregnancy (early) and for a longer duration have greater risk of adverse birth outcomes
compared to those with exposure in the third trimester of pregnancy (late) and for a
shorter duration.
A separate analysis was conducted for each adverse outcome comparing exposure to
antidepressant during first, second and third trimester to test the third hypothesis. The
analyses were conducting using logistic regression and marginal structural models,
controlling for duration of exposure in each trimester. Adjusted odds ratio along with
95% confidence intervals were calculated for the association between antidepressant use
during pregnancy and risk of each adverse birth outcomes for 1st, 2nd and 3rd trimesters.
Mother’s age, parity, mother’s weight, mother’s education, year of birth, total number of
risk factors, and previously poor birth outcomes were found to be significant in the
analysis. Also additional analysis was conducted with women who received
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antidepressants only in Trimester 1 or 2 or 3, using women who got antidepressants only
in the first trimester.
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CHAPTER 4
RESULTS
Study population consisted of pregnant women with a diagnosis of depression,
continuously enrolled in Medicaid for the entire term of their pregnancy, during the years
2008 - 2014.

During the study period (2008-2014) a total of 411,003 births were

financed by SC Medicaid. The prevalence of depression among pregnant women in the
SC Medicaid population was 26.2% that is approximately 107,683 women had a
diagnosis of depression before or during pregnancy. After applying the study inclusion
and exclusion criteria, the study sample comprised of 4,450 women. Out of the 4,450
women included in our analysis, 1,743 had multiple pregnancies during the study period.
About half of these women (901) had two pregnancies during the study period, 549 had
three pregnancies and 293 had more than three pregnancies during the study period. Each
pregnancy had to fulfill the inclusion-exclusion criteria to be included in the study.
Table 1 presents the demographic and clinical characteristics of the study
population. A total of 1,641 women in the study population had received at least one
antidepressant during their pregnancy and were categorized as exposed. All the others
who did not receive any antidepressants during their pregnancy were categorized as
unexposed.
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The mean age of the study participants was relatively higher in the exposed group
compared to the unexposed group (27.6 years vs 24.5 years, respectively). A large
number of study participants fell in the age range of 18-28 years [unexposed – 2,250
(80.1%); exposed 1,049 (63.9%)]. Proportion of women aged ≥39 years was smaller
[unexposed: 27 (0.96%); exposed: 69 (4.2%)].
Overall, in both exposed and unexposed the proportion of non-Hispanic whites
was higher than that of non-Hispanic blacks, Hispanics and others. The proportion of
non-Hispanic whites was higher in the exposed (71%) as compared to the unexposed
group (60.2%), whereas the proportion of non-Hispanic blacks was relatively lower
exposed group (25.8%) as compared to the unexposed group (37.1%). The proportion of
Hispanics and other races was significantly lower in the both unexposed and exposed
groups.
BMI was obtained from the birth certificates that record the pre-pregnancy BMI
of the mother. About half of the study population was either overweight (BMI ≥ 25 to <
30) or obese (BMI of ≥ 30) [unexposed: 1,587 (56.5 %); exposed: 1,008 (61.2 %)]. These
results were consistent with observations of other studies that looked at prevalence of
obesity in women of the lower socioeconomic strata1-3. About one-third of the study
participants reported to have less than a high school education [unexposed: 1,170 (41.7
%); exposed: 589 (35.9 %)], and very few had a bachelor’s or a higher degree
[unexposed: 41 (1.5 %); exposed: 40 (2.4 %)].
According to Kotelchuck Index reported on the birth certificates, the level of
prenatal care was ‘adequate plus’ for more than 45% of the study population, whereas
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about 25% were reported to have received ‘inadequate’ or ‘intermediate’ prenatal care.
The distribution of population by the levels of prenatal care received was similar in the
exposed and unexposed groups.
In the study population the proportion of women smoking before pregnancy was
higher than the proportion of women smoking during pregnancy, although the smoking
status of a large majority of women was unknown for both before and after pregnancy.
Also, the proportions of smokers and non-smokers for both before and during pregnancy
were similar in the exposed and unexposed groups.
The prevalence of gestational diabetes was relatively lower in the study
population and did not differ significantly between the exposed and unexposed groups4-5.
However the proportion of women affected by gestational hypertension is within the
range projected by the Center of Disease Control (CDC), which is about 5% to 7%6-7.
The prevalence of pre-pregnancy diabetes and pre-pregnancy hypertension is similar to
the prevalence estimated for women below the age of 50 by CDC8-10.
In about 33% of the women in both the exposed and unexposed group the
pregnancy being considered in the study was their second pregnancy. The proportion of
first pregnancies considered for study was lower in the exposed group (15.5%) as
compared to the unexposed group (27.8%). Higher parity (≥ 3 children) was
comparatively more prevalent in the exposed group (4.1%) compared to the unexposed
group (2.5 %).
The history of a poor birth outcomes such as pre-term delivery, low birth
weight/small for gestational age, NICU admissions or structural malformations, was
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relatively higher in the exposed group (16%) as compared to the unexposed group (12.7
%).
The distribution of infant gender was similar across exposed and unexposed
groups, the proportion of females (~ 51%) was slightly higher than males (~ 48%).
However, the distribution of infants born in exposed and unexposed groups was
significantly different each year from 2008-2014. This corresponds with the trend of
increase in the number of antidepressant prescribed during pregnancy from 2008-20141112

.
Selective Serotonin Reuptake Inhibitors (SSRIs) were the most commonly

prescribed antidepressants during pregnancy. A total of 1,152 (69%) of the study
participants in the exposed group were prescribed SSRIs. Atypical Antidepressants were
prescribed to 254 (15.5%), followed by Selective Norepinephrine Reuptake Inhibitors
(SNRIs) prescribed to 171 (10.4%) and Tricyclic Antidepressants (TCAs) prescribed to
83 (2.1%) study participants. (See Table 1)
Table 4.1 Demographic and Clinical Characteristic of Pregnant Women with a
Diagnosis of Depression Enrolled in SC Medicaid during their entire term of
Pregnancy
No
Antidepressants
Antidepressant
Prescribed During p-value
Maternal/Infant
Use During
Pregnancy
Characteristics
Pregnancy
N (%)
N (%)
2809 (100%)
1641 (100%)
Total
Mother's Age (Years)
18 – 28
2250 (80.10%)
1049 (63.92%)
<0.001
29 – 38
532 (18.94%)
523 (31.87%)
<0.001
≥ 39
27 (0.96%)
69 (4.20%)
<0.001
Mother's Weight
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Maternal/Infant
Characteristics
Underweight
Normal
Overweight
Obese
Mother's Education
Less than High School
High School or GED
High School + Some
College
Bachelor's Degree or
More
Prenatal Care
(Kotelchuck Index)
Inadequate
Intermediate
Adequate
Adequate Plus
Smoking Status
Pre-pregnancy
During Pregnancy
Diabetes
Pre-pregnancy
Gestational
Hypertension
Pre-pregnancy
Gestational
Parity
First
Second
Third
More than Three
Number of Risk
Factors
None
One
Two

No
Antidepressant
Use During
Pregnancy
N (%)
232 (7.62%)
990 (35.24%)
654 (23.28%)
933 (33.21%)

Antidepressants
Prescribed During
Pregnancy

p-value

N (%)
105 (6.40%)
528 (32.18%)
414 (25.23%)
594 (36.20%)

<0.001
<0.001
<0.001
<0.001

1170 (41.65%)
917 (32.65%)

589 (35.89%)
560 (34.13%)

<0.001
<0.001

681 (24.24%)

452 (27.54%)

<0.001

41 (1.46%)

40 (2.44%)

<0.001

611 (21.75%)
214 (7.62%)
663 (23.60 %)
1321 (47.03%)

331 (20.17%)
109 (6.64%)
388 (23.64%)
813 (49.54%)

<0.001
<0.001
<0.001
<0.001

1117 (39.77%)
981 (34.92%)

664 (40.46%)
601 (36.62%)

0.05
0.05

45 (1.60%)
137 (4.88%)

46 (2.8%)
79 (4.81%)

0.05
0.05

82 (2.92%)
163 (5.8 %)

61 (3.72%)
82 (5 %)

<0.001
<0.001

782 (27.8%)
972 (34.6%)
606 (21.6%)
449 (16 %)

254 (15.5 %)
536 (32.7%)
446 (27.2%)
405 (24.7%)

0.05
0.05
<0.001
<0.001

1514 (53.9%)
959 (34.1%)
267 (9.5%)

804 (49%)
595 (36.3%)
175 (10.7%)

0.166
0.166
0.166
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Maternal/Infant
Characteristics

No
Antidepressant
Use During
Pregnancy
N (%)
69 (2.5%)

Antidepressants
Prescribed During
Pregnancy
N (%)
67 (4.1%)

p-value

Three or more
0.166
Previous Poor
356 (12.7%)
262 (16%)
0.178
Outcomes
Infant Sex
Male
1448 (51.6%)
852 (52%)
<0.001
Female
1361 (48.5%)
789 (48.1%)
<0.001
Mother’s Race
Non-Hispanic White
1690 (60.2%)
1166 (71%)
<0.001
Non-Hispanic Black
1043 (37.1%)
423 (25.8%)
<0.001
Hispanic
60 (2.1%)
36 (2.2%)
<0.001
Other
16 (0.6%)
16 (1%)
<0.001
Year of Birth
2008
444 (15.8%)
143 (8.7%)
0.431
2009
437 (15.6%)
176 (10.7%)
0.512
2010
427 (15.2%)
184 (11.2%)
0.223
2011
457 (16.3%)
233 (14.2%)
0.021
2012
426 (15.2%)
253 (15.4%)
0.021
2013
309 (11%)
311 (19%)
0.356
2014
309(11%)
341 (20.8%)
0.511
Antidepressant Use
Selective Serotonin
N/A
1132 (69%)
N/A
Reuptake Inhibitors
Atypical
N/A
254 (15.5%)
N/A
Antidepressants
Serotonin–
norepinephrine Reuptake
N/A
171 (10.4%)
N/A
Inhibitor
Tricyclic
N/A
83 (5.1%)
N/A
Antidepressants
Note: Risk Factors: poor pre-natal care; previous adverse birth outcomes; gestational
diabetes, gestational hypertension, race, mother’s age, and mother’s BMI, previous
poor birth outcomes, etc. Previous Poor Birth Outcomes: pre-term delivery; low birth
weight/small for gestational age; structural malformations; NICU admissions.; N/A –
Not applicable; NICU – Neonatal Intensive Care Unit
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4.1 RESULTS FOR HYPOTHESIS 1

Study Hypothesis 1: Depressed women exposed to antidepressants during
pregnancy have a higher risk of adverse birth outcomes compared to women not exposed
to antidepressants during pregnancy.
The prevalence of adverse birth outcomes was higher in the exposed group
compared to the unexposed group (See Table 2). The prevalence of preterm birth was
17.25% in the exposed group versus 14.31% in the unexposed group (p-value < 0.01).
The number of NICU admissions was also higher in the exposed group (8.23%) as
compared to the unexposed group (7.62%) (p-value < 0.01). A similar pattern was
observed in the low birth weight/small for gestational age infants; the proportion was
found to be 17.25% in the exposed group whereas it was 16.59% in the unexposed group
(p-value < 0.01) (See Table 2).
These differences in the proportion remained significant after controlling for
various confounders such as mother’s age, mother’s education, parity, mother’s weight,
mother’s race, mother’s smoking status during pregnancy and before pregnancy,
gestational diabetes and hypertension, adequacy of prenatal care estimated using the
Kotelchuck Index etc. A logistic regression was conducted for each outcome controlling
for significant confounders.

In addition, another analysis was conducted using the

marginal structural models to delineate the effect of antidepressants on the birth outcomes
from the effect of maternal depression. Both the analysis yielded similar results (See
Table 2).
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The results for marginal structural models were similar to the results produced
using logistic regression. The point estimates were slightly higher, showing stronger
association and the confidence intervals were narrower (See Table 2).
4.1.1 Prenatal Exposure to Antidepressants and the Risk of Preterm Delivery

When conducting analysis using logistic regression the odds of having preterm
delivery were 1.58 (95%CI: 1.19 – 2.10) times higher in the study participants that
received an antidepressant during pregnancy as compared to those who did not receive
any antidepressants at any time during the pregnancy.
Whereas, according to the analysis conducted using marginal structural models,
the odds of preterm delivery were 1.72 times (95% CI: 1.63 – 1.79) in the group that
received antidepressants during pregnancy as compared to the group that did not receive
an antidepressant during pregnancy.
4.1.2 Prenatal Exposure to Antidepressants and the Risk of Low Birth Weight/Small
for Gestational Age
Using logistic regression it was estimated that antidepressant use during
pregnancy was associated with higher odds of the infant having low birth weight/being
small for gestational age- OR = 1.57 (95% CI: 1.42 – 2.76.)
Similar result was observed when the analysis was conducted using marginal
structural models. the odds of having low birth weight/being small for gestational age
were 1.63 times higher in the exposed group (95%CI: 1.53 – 1.73) as compared to the
unexposed group.
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4.1.3 Prenatal Exposure to Antidepressants and the Risk of NICU Admissions

A similar pattern was observed in the probability of NICU admissions. According
to the analysis conducted using logistic regression the odds of an infant being admitted to
NICU were almost twice in the exposed group as compared to the unexposed group (OR:
1.45; 95%CI 1.28 – 2.26).
According to marginal structural models, the estimated probability of being
admitted in NICU was 1.66 times higher with prenatal exposure to antidepressants than
without (95% CI: 1.58 – 1.73).
Table 4.2 Risk of having adverse birth outcomes between depressed pregnant women
exposed to antidepressants during pregnancy and those who were not exposed to
antidepressants during pregnancy
Used
No
AntidepresMarginal
Antidepressant
Logistic
Adverse Birth
sants
Structural
Use During
Regression
Outcomes
During
Model
Pregnancy
OR (95% CI)
Pregnancy
OR (95% CI)
N (%)
N (%)
283
Pre-term
1.58
1.72
402 (14.31%)
(17.25%)
(1.19 – 2.10)
(1.63 – 1.79)
Delivery
Low Birth
283
1.57
1.63
466 (16.59%)
Weight/ Small for
(17.25%)
(1.42 – 2.76)
(1.53 – 1.73)
Gestational Age
1.45
1.66
214 (7.62%) 135 (8.23%)
(1.28 – 2.26)
(1.58 – 1.73)
NICU Admission
Note: OR – Odds Ratio; NICU – Neonatal Intensive Care Unit; CI – Confidence
Interval
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4.1.4 Summary
The prevalence of adverse birth outcomes was higher in the exposed group as
compared to the unexposed group. Conducting a logistic regression controlling for all the
confounders confirmed the association of the prenatal exposure to antidepressants and an
increased risk of adverse birth outcomes. The odds of having an adverse birth outcome
ranged from 1.45 (95%CI: 1.28 – 2.26) to 1.72 (95%CI: 1.63 – 1.79). Delineating the
effect of antidepressants from depression using marginal structural models showed a
stronger association and had narrower confidence intervals as compared to logistic
regression.

4.2 RESULTS FOR HYPOTHESIS 2
Study Hypothesis 2: The risk of having adverse birth outcomes is higher in women
prescribed Selective Serotonin Reuptake Inhibitors compared to those depressed women
who have been prescribed other types of antidepressants.
As previously discussed SSRIs were the most commonly prescribed
antidepressants during pregnancy [1152 (68.99%)]. Atypical antidepressants and SNRIs
were prescribed to relatively fewer study participants [254 (15.48%) and 171 (10.42%)
respectively], TCAs were the least commonly prescribed antidepressants [83 (2.06%)].
4.2.1 Risk of Preterm Delivery Associated with Type of Antidepressants Prescribe
during Pregnancy
The risk of having a preterm delivery was higher for all antidepressant classes
when compared to the unexposed group. Analysis conducted using logistic regression
showed that the odds of having a preterm delivery were 1.95 (95% CI: 1.32 – 2.66) times
84

higher in study participants that received SSRIs during pregnancy as compared to those
who did not receive an antidepressant during pregnancy. Atypical antidepressant were
associated with the 1.89 (95%CI: 1.23 – 2.69) times higher odds of having a preterm birth
as compared to those who did not receive any antidepressants during pregnancy. SNRIs
and TCAs showed a similar association. The odds of preterm birth 1.80 (95%CI: 1.23 –
2.69) times higher in the SNRIs group, and 1.75 (95%CI: 1.32 – 2.89) times higher in the
TCA group as compared to those who were not prescribed any antidepressant during
pregnancy.
Using marginal structural models a similar pattern was observed. The odds of
having preterm delivery were 1.95 (95% CI: 1.71 – 2.15) times higher in the SSRIs
group, 1.85 (95% CI: 1.45 – 2.11) times higher in the atypical antidepressants group, 1.75
(95% CI: 1.47 – 2.00) times higher in the SNRIs group, and 1.81 (95% CI: 1.78 – 2.01)
times higher in the TCAs group when each group was compared to those who did not
receive any antidepressants during pregnancy.
When a logistic regression was conducted using SSRIs as the referent group, we
found that the odds of having preterm birth were not significantly associated with the
class of antidepressants prescribed during pregnancy. Atypicals and SNRI groups were
associated with 1.03 (95% CI: 0.67 – 1.54) times higher odds, and 0.95 (95% CI: 0.74 –
1.82) times higher odds than the SSRIs group. However, these results were not significant
as the odds are close to 1 and the confidence interval contains 1. Although not
statistically significant, TCAs were associated with relatively lower odds of having a
preterm delivery than SSRIs [OR: 0.89 (95% CI: 0.69 – 1.00)].
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The group that was prescribed TCAs during pregnancy had lower odds of having
preterm delivery as compared to those who were prescribed SSRIs during pregnancy
[OR: 0.85 (95% CI: 0.65 – 0.97)]. Atypicals and SNRI groups were associated with 1.08
(95% CI: 0.98 – 1.23) times higher odds, and 1.05 (95% CI: 0.85 – 1.19) times higher
odds than the SSRIs group.
Table 4.3 Comparison of Risk of Preterm Delivery between Types of Antidepressants
Prescribed during Pregnancy
Risk of Preterm Delivery associated with Class of Antidepressant Prescribed
during Pregnancy
Referent Group Referent Group - Unexposed
SSRIs
Class of
Antidepre
Marginal
Marginal
Logistics
Logistics
-ssants
Structural
Structural
#
Regression
Regression
Prescribed
Model OR
Model OR (95%
OR (95% CI)
OR (95% CI)
during
(95% CI)
CI)
Pregnancy
SSRIs

933

1.95
(1.32 – 2.66)

1.95
(1.71 – 2.15)

---

Atypicals

216

1.89
(1.23 – 2.69)

1.85
(1.45 – 2.11)

1.03
(0.67 – 1.54)

1.08
(0.98 – 1.23)

SNRIs

140

1.80
(1.21 – 2.03)

1.75
(1.47 – 2.00)

0.95
(0.74 – 1.82)

1.05
(0.85 – 1.19)

---

1.75
1.81
0.89
0.85
(1.32 – 2.89) (1.78 – 2.01) (0.69 – 1.00)
(0.65 – 0.97)
Note: OR – Odds Ratio; NICU – Neonatal Intensive Care Unit; CI – Confidence
Interval
TCAs

68
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4.2.2 Risk of Low Birth Weight/Small for Gestational Age Associated with Type of
Antidepressants Prescribe during Pregnancy
Analysis conducted using logistic regression showed that the odds of having a low
birth weight/small for gestational age were 1.78 (95%CI: 1.45 – 2.78) times higher in
study participants that received SSRIs during pregnancy as compared to those who did
not receive an antidepressant during pregnancy. Atypical antidepressant were associated
with the 1.65 (95% CI: 1.21 – 2.69) times higher odds of having a low birth weight/small
for gestational age as compared to those who did not receive any antidepressants during
pregnancy. SNRIs and TCAs showed a similar association. The odds of low birth
weight/small for gestational age 1.69 (95% CI: 1.41 – 2.78) times higher in the SNRIs
group, and 1.66 (95% CI: 1.25 – 2.12) times higher in the TCA group as compared to
those who were not prescribed any antidepressant during pregnancy.
Using marginal structural models a similar pattern was observed. The odds of
having low birth weight/small for gestational age were 1.80 (95%CI: 1.52 – 1.97) times
higher in the SSRIs group, 1.70 (95%CI: 1.32 – 1.86) times higher in the atypical
antidepressants group, 1.73 (95%CI: 1.50 – 1.89) times higher in the SNRIs group, and
1.71 (95%CI: 1.68 – 1.89) times higher in the TCAs group when each group was
compared to those who did not receive any antidepressants during pregnancy.
When a logistic regression was conducted using SSRIs as the referent group, we
found that the odds of having low birth weight/small for gestational age were not
significantly associated with the class of antidepressants prescribed during pregnancy.
Atypicals and SNRI groups were associated with 1.06 (95% CI: 0.59 – 1.66) times higher
odds, and 1.02(95% CI: 0.64 – 1.62) times higher odds than the SSRIs group. TCAs were
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associated with relatively lower odds of having a low birth weight/small for gestational
age than SSRIs [OR: 0.91 (95% CI: 0.68 – 1.10)]. The results were not statistically
significant.
According to the marginal structural models it was found that group that was
prescribed TCAs during pregnancy had lower odds of having low birth weight/small for
gestational age as compared to those who were prescribed SSRIs during pregnancy [OR:
0.95 (95% CI: 0.89 – 1.05)]. Atypicals and SNRI groups were associated with 1.07 (95%
CI: 0.75 – 1.14) times higher odds, and 1.05 (95% CI: 0.79 – 1.18) times higher odds
than the SSRIs group. However, these results were not statistically significant.
Table 4.4 Comparison of Risk of Low Birth Weight/Small for Gestational Age between
Types of Antidepressants Prescribed during Pregnancy
Risk of Risk of Low Birth Weight/Small for Gestational Age associated with
Class of Antidepressant Prescribed during Pregnancy
Referent Group Referent Group - SSRIs
Unexposed
Class of
AntideprMarginal
Marginal
Logistics
Logistics
essants
Structural
Structural
#
Regression
Regression
Prescribed
Model OR
Model OR
OR (95% CI)
OR (95% CI)
during
(95% CI)
(95% CI)
Pregnancy
SSRIs

935

1.78
(1.45 – 2.78)

1.80
(1.52 – 1.97)

---

Atypicals

211

1.65
(1.21 – 2.56)

1.70
(1.32 – 1.86)

1.06
(0.59 – 1.66)

1.07
(0.75 – 1.14)

SNRIs

141

1.69
(1.41 – 2.78)

1.73
(1.50 –1.89)

1.02
(0.64 – 1.62)

1.05
(0.79 – 1.18)

---

1.66
1.71
0.91
0.95
(1.75 – 2.12)
(1.68 – 1.89) (0.68 – 1.10)
(0.89 – 1.05)
Note: OR – Odds Ratio; NICU – Neonatal Intensive Care Unit; CI – Confidence
Interval
TCAs

70
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4.2.3 Risk of NICU Admissions Associated With Type of Antidepressants Prescribe
during Pregnancy

Analysis conducted using logistic regression showed that the odds of having a
NICU admissions were 1.92 (95% CI: 1.41 – 2.54) times higher in study participants that
received SSRIs during pregnancy as compared to those who did not receive an
antidepressant during pregnancy. Atypical antidepressant were associated with the 1.71
(95% CI: 1.32 – 2.76) times higher odds of having a NICU admissions as compared to
those who did not receive any antidepressants during pregnancy. SNRIs and TCAs
showed a similar association. The odds of NICU admissions 1.83 (95%CI: 1.33 – 2.75)
times higher in the SNRIs group, and 1.75 (95% CI: 1.65 – 2.72) times higher in the TCA
group as compared to those who were not prescribed any antidepressant during
pregnancy.
Using marginal structural models a similar pattern was observed. The odds of
having NICU admissions were 1.80 (95%CI: 1.52 – 1.97) times higher in the SSRIs
group, 1.80 (95% CI: 1.77 – 2.00) times higher in the atypical antidepressants group, 1.77
(95% CI: 1.32 – 1.97) times higher in the SNRIs group, and 1.84 (95% CI: 1.39 – 1.99)
times higher in the TCAs group when each group was compared to those who did not
receive any antidepressants during pregnancy.
When a logistic regression was conducted using SSRIs as the referent group, we
found that the odds of having NICU admissions were not significantly associated with the
class of antidepressants prescribed during pregnancy. Atypicals were associated with 1.04
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(95% CI: 0.67 – 1.52) times higher odds than the SSRIs group. Whereas, TCAs and
SNRI were associated with relatively lower odds of having a NICU admissions than
SSRIs [OR: 0.89 (95% CI: 0.63 – 1.12); OR: 0.95 (95% CI: 0.85 – 1.10) respectively].
However, the results were not statistically significant.
According to the marginal structural models it was found that group that was
prescribed TCAs and SNRIs during pregnancy had lower odds of having NICU
admissions as compared to those who were prescribed SSRIs during pregnancy [OR:
0.91 (95% CI: 0.87 – 1.09); OR: 0.98 (95% CI: 0.85 – 1.23) respectively]. Atypicals were
associated with 1.06 (95% CI: 0.85 – 1.10) times higher odds than the SSRIs group.
However, these results were not statistically significant.
Table 4.5 Comparison of Risk of NICU Admissions between Types of Antidepressants
Prescribed during Pregnancy
Risk of NICU Admissions associated with Class of Antidepressant Prescribed
during Pregnancy
Referent Group Referent Group - Unexposed
SSRIs
Class of
Antidepres
Marginal
Marginal
Logistics
Logistics
-sants
Structural
Structural
#
Regression OR
Regression
Prescribed
Model OR
Model OR
(95% CI)
OR (95% CI)
during
(95% CI)
(95% CI)
Pregnancy
SSRIs

95

1.92
(1.41 – 2.54)

1.89
(1.77 – 2.00)

Atypicals

16

1.71
(1.32 – 2.76)

1.80
(1.32 – 1.97)

1.04
(0.67 – 1.52)

1.06
(0.85 – 1.10)

SNRIs

15

1.83
(1.33 – 2.75)

1.84
(1.39 – 1.99)

0.95
(0.85 – 1.10)

0.98
(0.85 – 1.23)

TCAs

9

1.75
(1.65 – 2.72)

1.79
(1.67 – 1.96)

0.89
(0.63 – 1.12)

0.91
(0.87 – 1.09)
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---

---

Note: OR – Odds Ratio; NICU – Neonatal Intensive Care Unit; CI – Confidence
Interval

4.2.4 Summary

When each class of antidepressant was independently compared to the unexposed
group, it was found that all the classes of antidepressants were associated with a higher
risk of adverse birth outcomes. Both logistic regression and marginal structural models
yielded similar results. Upon comparing the different classes of antidepressants to SSRIs
we found that the risk of adverse birth outcomes was not significantly different between
the different types of antidepressants. Only TCAs had a statistically lower risk of NICU
admissions as compared to SSRIs. Using marginal structural models we found that the
risk of NICU admissions was 0.85 times (95% CI: 0.65 – 0.97) lower in TCAs as
compared to SSRIs. These results are can attributed to a variety of reasons, TCA were
prescribed to relatively fewer people as compared to the other antidepressants. Also,
TCAs prescription has reduced over the past decade and is mostly prescribed to older
women. Mother’s of age above 40 are more likely to have poor birth outcomes; this
might dilute the association of TCAs and risk of adverse birth outcomes.
4.3 RESULTS FOR HYPOTHESIS 3

Hypothesis 3: Depressed women who have late pregnancy exposure and for a
longer duration have greater risk of adverse birth outcomes compared to those with
comparatively early pregnancy exposure and shorter duration.
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A majority of the study participants received antidepressants during the third
trimester of their pregnancy 781, followed by the second trimester 620, and only 158
study participants received antidepressants during the first trimester.
4.3.1 Prenatal Exposure to Antidepressants in the First Trimester of Pregnancy and
Risk of Preterm Delivery

According to the analysis conducted using logistic regression it was found that the
odds of having preterm delivery were 1.98 times higher (95%CI: 1.2 – 2.1) in the group
that was exposed to antidepressants during the first trimester of pregnancy as compared
to women who did not receive any antidepressants during the first trimester. Duration of
exposure was not significantly associated with the risk of preterm term delivery (OR:
1.07 95%CI: 0.84 – 1.37).
Similar results were observed when the analysis was conducted using marginal
structural models. The odds of having a preterm delivery were 1.8 times (95% CI: 1.5 –
2.1) higher in women who received an antidepressant during the first trimester of
pregnancy as compared to those who did not receive any antidepressants during the first
trimester of pregnancy. Duration of exposure was not significantly associated with the
risk of preterm term delivery in the first trimester (OR: 1.13 95%CI: 0.94 – 1.28).
4.3.2 Prenatal Exposure to Antidepressants in the First Trimester of Pregnancy and
Risk of Low Birth Weight/Small for Gestational Age
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Using logistic regression is was estimated that the probability of having low birth
weight/small for gestational age infants was 1.99 (95%CI: 1.9 – 2.4) times higher in the
group exposed to antidepressants during the first trimester of pregnancy as compared to
those who did not receive an antidepressant during the first trimester of pregnancy. Each
unit increase in the duration of exposure in the first trimester was associated with 1.19
times higher odds of having low birth weight/small for gestational age (95%CI 0.95 –
1.48), although the association was not statistically significant.
According to marginal structural models, the odds of having low birth
weight/small for gestational age were 1.95 times higher (95%CI 1.6- 2.2) in the group
receiving antidepressants during the first trimester of pregnancy as compared to the group
which did not receive any antidepressants during first trimester of pregnancy. A unit
increase in the duration of exposure to antidepressants was not significantly associated
with the risk of low birth weight/small for gestational age (OR: 1.21 95%CI: 0.97 – 1.28).
4.3.3 Prenatal Exposure to Antidepressants in the First Trimester of Pregnancy and
Risk of NICU Admission

According to logistic regression the risk of NICU admissions was estimated to be
1.8 (95%CI: 1.5 – 2.2) times higher in the group exposed during the first trimester of
pregnancy as compared to those who were not exposed antidepressants during the first
trimester of pregnancy. Duration of exposure was not significantly associated with the
risk of NICU admissions in the first trimester of pregnancy (OR: 0.98 95%CI: 0.76 –
1.27).
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Similarly, the odds of NICU admission estimated using marginal structural
models were 1.6 (95%CI: 1.5 – 1.8) times higher in the group exposed to antidepressants
in the first trimester as compared to the group that did not receive any antidepressants
during the first trimester of the pregnancy. Duration of exposure was not significantly
associated with the risk of preterm term delivery in the first trimester (OR: 1.11 95%CI:
0.94 – 1.28).
Table 6 shows the odds of adverse birth outcomes such as preterm delivery, low birth
weight/small for gestational age and NICU admission associated with prenatal exposure
to antidepressants during the first trimester of pregnancy.
Table 4.6 Risk of having adverse birth outcomes among depressed pregnant women
exposed to antidepressants during first trimester of pregnancy and those who were not
exposed to any antidepressants during first trimester of their pregnancy
Risk Associated with Prenatal Exposure to Antidepressants in the First
Trimester of Pregnancy
Logistics Regression Marginal Structural Model
OR (95% CI)
OR (95% CI)
Pre-term Delivery

1.98
(1.2 – 2.1)

1.8
(1.5 – 2.1)

Low Birth Weight/ Small for
Gestational Age

1.99
(1.9 – 2.4)

1.95
(1.6 – 2.2)

NICU Admission

1.81
(1.5 – 2.2)

1.6
(1.3 – 2.1)

Note: OR – Odds Ratio; NICU – Neonatal Intensive Care Unit; CI – Confidence Interval
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4.3.4 Prenatal Exposure to Antidepressants in the Second Trimester of Pregnancy and
Risk of Preterm Delivery

Analysis conducted using logistic regression showed that the odds of having
preterm delivery were 1.8 (95%CI: 1.2 – 2.9) times higher in the group that was exposed
to antidepressants during the second trimester of pregnancy as compared to those who did
not receive any antidepressants during the second trimester. Duration of exposure was not
significantly associated with the risk of preterm term delivery in the second trimester
(OR: 1.09 95%CI: 0.77 – 1.57).
Similar results were observed when the analysis was conducted using marginal
structural models. The odds of having a preterm delivery were 1.6 (95% CI: 1.6 – 1.9)
times higher in women who received an antidepressant during the second trimester of
pregnancy as compared to those who did not receive any antidepressants during the
second trimester of pregnancy. Duration of exposure was not significantly associated
with the risk of preterm term delivery in the second trimester (OR: 1.12 95%CI: 0.92 –
1.25).
4.3.5 Prenatal Exposure to Antidepressants in the Second Trimester of Pregnancy and
Risk of Low Birth Weight/Small for Gestational Age
Using logistic regression is was estimated that the probability of having low birth
weight/small for gestational age infants was 1.8 (95%CI: 1.6 – 2.1) times higher in the
group exposed to antidepressants during the second trimester of pregnancy as compared
to those who did not receive an antidepressant during the second trimester of pregnancy.
Each unit increase in the duration of exposure in the second trimester was associated with
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1.36 times higher odds of having low birth weight/small for gestational age (95%CI 0.98
– 1.58), although the association was not statistically significant.
According to marginal structural models, the odds of having low birth
weight/small for gestational age were 1.7 (95%CI: 1.6 – 1.9) times higher in the group
receiving antidepressants during the second trimester of pregnancy as compared to the
group which did not receive any antidepressant during the second trimester of pregnancy.
A unit increase in the duration of exposure to antidepressants was not significantly
associated with the risk of low birth weight/small for gestational age (OR: 1.40 95% CI:
0.97 – 1.48).
4.3.6 Prenatal Exposure to Antidepressants in the Second Trimester of Pregnancy and
Risk of NICU Admission
According to logistic regression the risk of NICU admissions was estimated to be
1.7 (95%CI: 1.3 – 1.9) times higher in the group exposed during the second trimester of
pregnancy as compared to those who were not exposed antidepressants during the second
trimester of pregnancy. Duration of exposure was not significantly associated with the
risk of NICU admissions in the second trimester of pregnancy (OR: 1.24 95%CI: 0.86 –
1.61).
Similarly, the odds of NICU admission estimated using marginal structural
models were 1.7 (95%CI: 1.6 – 1.9) times higher in the group exposed to antidepressants
in the second trimester as compared to the group that did not receive any antidepressants
during the second trimester of the pregnancy.
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Table 7 shows the odds of adverse birth outcomes such as preterm delivery, low
birth weight/small for gestational age and NICU admission associated with prenatal
exposure to antidepressants during the second trimester of pregnancy. Duration of
exposure was not significantly associated with the risk of preterm term delivery in the
second trimester (OR: 1.31 95%CI: 0.98 – 1.39).
Table 4.7 Risk of having adverse birth outcomes among depressed pregnant women
exposed to antidepressants during second trimester of pregnancy and those who were
not exposed to any antidepressants during second trimester of their pregnancy
Risk Associated with Prenatal Exposure to Antidepressants in the Second
Trimester of Pregnancy
Logistics
Marginal Structural Model
Regression
OR (95% CI)
OR (95% CI)
Pre-term Delivery

1.75
(1.16 – 2.88)

1.64
(1.61 – 1.86)

Low Birth Weight/ Small for
Gestational Age

1.76
(1.55 – 2.10)

1.73
(1.61 – 1.86)

NICU Admission

1.66
(1.32 – 1.92)

1.73
(1.58 – 1.92)

Note: OR – Odds Ratio; NICU – Neonatal Intensive Care Unit; CI – Confidence Interval
4.3.7 Prenatal Exposure to Antidepressants in the Third Trimester of Pregnancy and
Risk of Preterm Delivery
Analysis conducted using logistic regression showed that the odds of having
preterm delivery were 1.66 (95%CI: 1.58 – 2.84) times higher in the group that was
exposed to antidepressants during the third trimester of pregnancy as compared to those
who did not receive any antidepressants during the third trimester. Duration of exposure
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was not significantly associated with the risk of preterm term delivery (OR: 1.07 95%CI:
0.76 – 1.49).
Similar results were observed when the analysis was conducted using marginal
structural models. The odds of having a preterm delivery were 1.64 (95% CI: 1.58 – 1.80)
times higher in women who received an antidepressant during the third trimester of
pregnancy as compared to those who did not receive any antidepressants during the third
trimester of pregnancy. Duration of exposure was not significantly associated with the
risk of preterm term delivery in the third trimester (OR: 1.14 95%CI: 0.95 – 1.35).
4.3.8 Prenatal Exposure to Antidepressants in the Third Trimester of Pregnancy and
Risk of Low Birth Weight/Small for Gestational Age
Using logistic regression is was estimated that the probability of having low birth
weight/small for gestational age infants was 1.76 (95%CI: 1.32 – 1.99) times higher in
the group exposed to antidepressants during the third trimester of pregnancy as compared
to those who did not receive an antidepressant during the third trimester of pregnancy.
Each unit increase in the duration of exposure in the first trimester was associated with
1.24 times higher odds of having low birth weight/small for gestational age (95% CI:
0.78 – 1.37), although the association was not statistically significant.
According to marginal structural models, the odds of having low birth
weight/small for gestational age were 1.66 (95%CI: 1.57 – 1.79) times higher in the
group receiving antidepressants during the third trimester of pregnancy as compared to
the group which did not receive any antidepressant during the third trimester of
pregnancy. A unit increase in the duration of exposure to antidepressants was not
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significantly associated with the risk of low birth weight/small for gestational age (OR:
1.32 95% CI: 0.99 – 1.27).
4.3.9 Prenatal Exposure to Antidepressants in the Third Trimester of Pregnancy and
Risk of NICU Admission
According to logistic regression the risk of NICU admissions was estimated to be
1.59 (95%CI: 1.14 – 2.00) times higher in the group exposed during the third trimester of
pregnancy as compared to those who were not exposed antidepressants during the third
trimester of pregnancy. Duration of exposure was not significantly associated with the
risk of NICU admissions in the third trimester of pregnancy (OR: 1.35 95%CI: 0.87 –
1.95).
Similarly, the odds of NICU admission estimated using marginal structural
models were 1.63 (95% CI: 1.50 – 1.80) times higher in the group exposed to
antidepressants in the third trimester as compared to the group that did not receive any
antidepressants during the third trimester of the pregnancy. Duration of exposure was not
significantly associated with the risk of preterm term delivery in the third trimester (OR:
1.39 95%CI: 0.96 – 1.45).
Table 8 shows the odds of adverse birth outcomes such as preterm delivery, low
birth weight/small for gestational age and NICU admission associated with prenatal
exposure to antidepressants during the third trimester of pregnancy.
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Table 4.8 Risk of having adverse birth outcomes among depressed pregnant women
exposed to antidepressants during third trimester of pregnancy and those who were not
exposed to any antidepressants during third trimester of their pregnancy
Risk Associated with Prenatal Exposure to Antidepressants in the Third
Trimester of Pregnancy
Logistics Regression
OR (95% CI)

Marginal Structural Model
OR (95% CI)

Pre-term Delivery

1.66
(1.58 – 2.84)

1.64
(1.58 – 1.80)

Low Birth Weight/ Small
for Gestational Age

1.76
(1.32 – 1.99)

1.66
(1.57 – 1.79)

NICU Admission

1.59
(1.14 – 2.00)

1.63
(1.50 – 1.80)

Note: OR – Odds Ratio; NICU – Neonatal Intensive Care Unit; CI – Confidence Interval

Prenatal exposure to antidepressants was found to be associated with adverse birth
outcomes such as preterm delivery, low birth weight/small for gestational age, and NICU
admissions in all the three trimesters. The duration of exposure, that is the number of
days the antidepressant was prescribed during a semester was not significantly associated
with the risk of adverse birth outcomes. However, further analysis is required to
determine the relatively safe time of exposure to antidepressants in order to minimize the
risk of adverse birth outcomes such as preterm delivery, low birth weight/small for
gestational age, and NICU admissions.
4.3.10 Additional Analysis

Additional analysis was conducted using only those women who had been
prescribed antidepressants in only one trimester of their pregnancy. That is, women who
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received antidepressants only in Trimester 1 were compared to women who received
antidepressants only in Trimester 2 and women who received antidepressants only in
Trimester 3, using women who got antidepressants only in Trimester 1 as the reference
group. Using logistic regression we found that the risk of having low birth weight/small
for gestational age was 1.3 (95% CI: 1.09 – 1.45) times higher in the third trimester as
compared to the first trimester. Also, the risk was 1.2 (95% CI: 1.11 – 1.59) times higher
in the second trimester as compared to the first trimester. According to marginal
structural models the risk of low birth weight/small gestational age was 1.42 (95% CI:
1.38 – 1.54) times higher in the third trimester and 1.31 (95% CI: 1.26 – 1.39) times
higher in the second trimester as compared to the first trimester.
Similar results were observed for NICU admissions. Logistic regression showed
that the risk of NICU admissions were 1.21 (95% CI: 1.07 – 1.61) times higher in the
third trimester and 1.19 (95% CI: 1.10 – 1.57) times higher in the second trimester as
compared to the first trimester. Using marginal structural models the risk of NICU
admission was found to 1.29 (95% CI: 1.20 – 1.37) times higher with exposure in the
third trimester and 1.25 (95% CI: 1.19 – 1.40) times higher with exposure in the second
trimester as compared to the first trimester.
The association of duration was still not statistically significant. The risk of
adverse birth outcomes was not affected by the number of days antidepressant was
prescribed in the each trimester. This additional analysis was not conducted for preterm
delivery due to the nature of the outcome it would be difficult to accurately estimate the
exposure.
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Table 4.9 Comparison of Risk of Low Birth Weight/ Small for Gestational Age and
NICU Admissions between Trimesters of Exposure to Antidepressants
Risk of Low Birth Weight/Small for Gestational Age and NICU Admission by
Trimester of Antidepressant Exposure (Using Trimester 1 as the Referent Group)
Trim
-ester
Trimester 2
Trimester 3
1
Marginal
Marginal
Adverse
Logistics
Logistics
Structural
Structural
Birth
Regression
Regression
Model OR
Model OR
Outcome
OR (95% CI)
OR (95% CI)
(95% CI)
(95% CI)
Low Birth
Weight/
1.2
1.31
1.3
1.42
Small for
RG
(1.11 – 1.59) (1.26 – 1.39) (1.09 – 1.45)
(1.38 – 1.54)
Gestational
Age
NICU
1.19
1.25
1.21
1.29
RG
(1.10 – 1.57) (1.19 – 1.40) (1.07 – 1.61)
(1.20 – 1.37)
Admissions
Note: OR – Odds Ratio; NICU – Neonatal Intensive Care Unit; CI – Confidence
Interval; RG – Reference Group

4.3.11 Summary

Exposure to antidepressants in all three trimesters was associated with the risk of
adverse birth outcomes. A separate analysis was conducted for each trimester, where the
women getting antidepressants in that semester were compared to those who were not
exposed to antidepressants at any time during their pregnancy. Duration in terms of the
number of days antidepressants were prescribed during the semester was controlled for as
a variable in the analysis. Duration of exposure was not associated with the risk of
adverse birth outcomes.
Conducting additional analysis using women who were prescribed antidepressants
only in one trimester of their pregnancy and first trimester was sued as the referent group.
We found that the risk of low birth weight/small for gestational age and NICU
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admissions was higher with exposure in the third and second trimester as compared to the
first trimester.
4.4 SUMMARY

Through both the methods of analysis we found that the risk of adverse birth
outcomes such as preterm delivery, low birth weight/small for gestational age and NICU
admissions were higher in the exposed group as compared to the unexposed group. The
odds of having an adverse birth outcome ranged from 1.45 (95%CI: 1.28 – 2.26) to 1.72
(95%CI: 1.63 – 1.79).
All classes of antidepressants that SSRIs, Atypicals, SNRIs, and TCAs when
compared to the unexposed group, were found to be associated with a higher risk of
adverse birth outcomes. Both logistic regression and marginal structural models yielded
similar results. Upon comparing the different classes of antidepressants to SSRIs we
found that the risk of adverse birth outcomes was not significantly different between the
different types of antidepressants. Only TCAs had a statistically lower risk of NICU
admissions as compared to SSRIs. Using marginal structural models we found that the
risk of NICU admissions was 0.85 times (95% CI: 0.65 – 0.97) lower in TCAs as
compared to SSRIs. These results are can attributed to a variety of reasons, TCA were
prescribed to relatively fewer people as compared to the other antidepressants. Also,
TCAs prescription has reduced over the past decade and is mostly prescribed to older
women.
Exposure to antidepressants in all three trimesters was associated with the risk of
adverse birth outcomes. Although the duration of exposure that is the number of days for
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which the antidepressant was prescribed in each trimester was not associated with the risk
of adverse birth outcomes. Conducting additional analysis we found that the risk of low
birth weight/small for gestational age and NICU admissions was higher with exposure in
the third and second trimester as compared to the first trimester.
Delineating the effect of antidepressants from depression using marginal
structural models showed a stronger association and had narrower confidence intervals as
compared to logistic regression.
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CHAPTER 5
DISCUSSION

Depression is a growing concern to healthcare professionals. It is a mental illness
that can be debilitating to patients, and is costly and challenging to treat. Women are 70%
more likely to suffer depression than men1. Depression has become a common problem
during and after pregnancy. Prevalence of depressive disorders in pregnant women ranges
from 14% to 23%2-4. Both depression and antidepressants have been associated with
adverse birth outcomes such as preterm delivery5-12, low birth weight/small for
gestational age5-12 and NICU admissions5,10-13. Over the past decade the proportion of
pregnancies with antidepressant use has increased from 5.7% of pregnancies to 13.4% of
pregnancies and is projected to increase further1-2,14. A similar trend was seen in our
study; prescription of antidepressants increased from 8.7% in 2008 to 20.8% in 2014.
Over the past decade several studies have assessed the association between prenatal
exposure to antidepressants and adverse birth outcomes, although the results have been
inconsistent15-24. These will be discussed below, and will provide context to the results
of the current study.
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5.1 IMPACT OF PRENATAL EXPOSURE TO ANTIDEPRESSANTS ON RISK
OF PRETERM DELIVERY
Several studies examine the incidence of preterm birth in women exposed to
antidepressants during pregnancy18,

25-32

. These include meta-analysis25, prospective

cohort studies26,27,30, retrospective cohort studies28-29,31, and case control studies32,18.
Some studies examined mean gestational age (rather than preterm delivery)30. In the
majority of studies, including the current study, prevalence of preterm delivery was
considered28-29,31-32. In our study we found that prenatal exposure to antidepressants is
significantly associated with an increased risk of preterm delivery. Similar results were
seen in a meta-analysis of nine studies that showed a significant increase in preterm births
with an OR 2.23 (95%CI 1.61 – 2.6)18. Several cohort studies which considered different
classes of antidepressants (SSRIs, Atypical, TCA and SNRI) demonstrated a statistically
significant increase in preterm delivery rates for all classes21-25, 34-36. In our study we drew
a similar conclusion, all the classes of antidepressants considered were significantly
associated with increased odds of preterm delivery. However, no other study estimated
the relative odds of different classes of antidepressants compared to one another. Two of
the afore mentioned studies showed a relationship between preterm delivery rates and late
exposure24,34. However in our study we did not find a statistically significant difference in
the risk of preterm delivery and trimester of exposure to antidepressants. A prospective
cohort study conducted revealed a correlation between preterm birth and chronic
exposure to antidepressants but not with short term exposure

37

. In our study we found

that duration of exposure was not significant, any exposure to antidepressants during
pregnancy was found to be associated with an increased risk of preterm delivery. Some
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studies also demonstrated a positive finding between duration of exposure and preterm
birth34-36. All of these studies have similar weaknesses, with no measures of actual drug
exposure or controls for confounders such as smoking and, in particular, the effects of
underlying depression. Some of the more rigorous studies have tried to tease out the role
of untreated maternal depression. In a study of 119, 547 prescription records matched
with hospital separation records, the authors found that SSRI-exposed babies had a higher
rate of preterm birth than babies exposed to depression alone (p > 0.01)29. Similarly,
another small prospective study compared women with depression alone and treatment
with SSRIs and found a statistically significant higher preterm birth rate in the exposed
infants (14% exposed group, 0% depressed group)38. In contrast, another small study did
not detect any difference between treated and depressed groups31. However, in our study
we found that the odds of having preterm delivery were significantly higher in depressed
women who had a prescription antidepressant during pregnancy as compared to those
who did not. Also, our study had the advantage of having a large sample size and detailed
drug information.

5.2 IMPACT OF PRENATAL EXPOSURE TO ANTIDEPRESSANTS ON RISK
OF BEING LOW BIRTH WEIGHT/SMALL FOR GESTATIONAL AGE

Similar to preterm delivery, a number of studies have examined the impact of
prenatal exposure to antidepressants on low birth weight and small for gestational age. A
meta-analysis showed a statistically significant risk of low birth weight for gestational
age18. Similar results were seen in our analysis, where we report that prenatal exposure to
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antidepressants was associated with an increased odds of low birth weight/small for
gestational age. Several other cohort studies had similar results26,28,29,33,39-41; and several
others had conflicting results15,18,24,30,34,43-44. In one study, authors attempted to increase
the sensitivity of the study by using propensity scoring to control for confounders and
found an effect on birth weight related to exposure35. Only two studies controlled for
confounders such as depression, smoking, maternal age or maternal weight, and these
showed no differences in birth weight in babies born to exposed or non-exposed
mothers44-45. These studies were limited by their sample size. An increased possible risk
of large birth weights following TCA treatment was reported in one study34. Although
partially related to higher body mass index in mothers taking antidepressants, the effect
did not completely disappear when this was controlled for. However these studies did not
control for drug class and duration of antidepressant prescribed.
It needs to be acknowledged here that low birth weight and small for gestational
age are not ideal measures for intrauterine growth; however, these are the two most
commonly used measures in the literature and are generally considered together36-39.
Studies show that the low birth weight is strongly associated with pre-term delivery; the
magnitude and direction of misclassification of low birth weight differed by preterm and
full term birth40-41. Small for gestational age has been considered to be relatively more
accurate than low birth weight as the weight of infants of the same gestational age is
compared40. In our study population there were 709 infants having low birth weight and
687 were small for gestational age. A total of 649 infants were diagnosed with both low
birth weight and being small for gestational age.
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5.3 IMPACT OF PRENATAL EXPOSURE TO ANTIDEPRESSANTS ON RISK
OF NICU ADMISSIONS
Relatively fewer studies have examined the association between admission to
NICU and prenatal exposure to antidepressants31,36,39,43-44. Most of the studies show some
association between prenatal exposure to antidepressants and neonatal adaptation
difficulties which can be measured in various ways, from gross markers such as NICU
admission to more subtle evaluations such as behavioral observations. This variability in
outcome measure makes it difficult to draw general conclusions. Large database or
registry studies have variously suggested a 1.5 times increased risk of NICU admission
with third trimester exposure compared to first trimester exposure

47

. However in our

study we found exposure to antidepressants during pregnancy, irrespective of trimester, is
associated with increased odds of having NICU admission. Similar to our results, a metaanalysis48 of prospective controlled trials included consideration of 1066 mother – infant
pairs and found a three-fold increased risk of SCN/NICU admission following
antidepressant exposure. However, none of the studies in the meta-analysis included a
depressed, non-drug-treated group. Two subsequent studies do include such a group. A
study conducted in 132 infants found that exposure to citalopram during pregnancy had a
four-fold increased incidence of NICU admission compared to matched infants exposed
to untreated maternal depression or controls30. Two other controlled studies did not find
an association between SSRIs exposure and NICU admission, however, these studies
were limited by sample size and were prone to recall bias as information was collected
through an interview with the mothers. Studies examining the impact of prenatal
exposure to TCAs are limited to case reports and case series. Several case reports
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describe an association between prenatal exposures to clomipramine49-50 and
imipramine51-52 with NICU admissions. With regard to the newer antidepressants,
evidence is scant. Some of the studies include venlafaxine exposure53-56 and suggest a
similar rate of NICU admissions as that associated with SSRIs. However, none of the
studies control for duration and time of exposure and do not estimate the relative impact
of the different types of antidepressants.
5.4 ADDRESSING THE GAPS IN THE LITERATURE
In our study, we found that the prenatal exposure to antidepressants is associated
with higher odds of having an adverse birth outcome such as preterm delivery, low birth
weight/small for gestational age, NICU admissions. This association was not affected by
the type of antidepressant prescribed or the trimester of exposure. Our study results are
consistent with several studies in the existing literature26,28,29,33,39-41, but are conflicting
with several others8-11,15,18,24,30,34,43-44. The current literature on the impact of prenatal
exposure to antidepressants on adverse birth outcomes has inconsistent results. There are
several possible reasons for these inconsistencies. First, studies have used a variety of
different methodologies18,57-59, which make them difficult to compare. Second, many
studies lack an appropriate control, which introduces many threats to internal validity18,5759

. Third, most of the studies look only at prenatal exposure to selective serotonin

reuptake inhibitors (SSRIs); there is limited information available on other classes of
antidepressants18,57-59. Fourth a number of studies have failed to control for confounders
such as maternal smoking, parity, and duration of exposure to antidepressants and most
importantly maternal depression18,57-59. Through our study we have tried to address these
gaps in the literature in the following ways:
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5.4.1 Controlling for Maternal Depression
Studies show that maternal depression can have an impact on the pregnancy and
fetus15. Untreated depression has been found to be associated with preterm delivery, low
birth weight and small for gestational age15-17.We controlled for maternal depression in
our study. The information on maternal depression was obtained from the SC Medicaid
claims database using the ICD 9 diagnosis. In addition we have used marginal structural
models to delineate the effect of antidepressants from the effect of depression itself on the
adverse birth outcomes62-63.
5.4.2. Larger Focus on SSRIs
Since SSRIs are the most commonly prescribed antidepressants, a majority of the
studies focus on the impact of prenatal exposure to SSRIs alone on adverse birth
outcomes. Although there is still information available about the impact of prenatal
exposure to TCAs, the information related to Atypical and SNRIs is scant. In our study
we have examined the association of prenatal exposure to all the classes of
antidepressants that SSRIs, Atypical, SNRIs, and TCAs. We also did a comparative
analysis using SSRIs as the reference group to estimate relative safety of the
antidepressants. We found that there is no statistically significant difference in risk of
adverse birth outcomes across the multiple drug classes, compared to SSRIs.
5.4.3. Inadequate Controlling for Confounders
Several of the studies examining the impact of prenatal exposure to
antidepressants on adverse birth outcomes fail to control for confounders such as
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smoking status, mother’s BMI, gestational diabetes, gestation hypertension, duration and
trimester of exposure to antidepressants etc. In our study we controlled for all of these
confounders. Through the linkage of SC Medicaid claims data with birth certificates we
were able to access important information such as mother’s smoking status before and
during pregnancy, gestational diabetes, gestational hypertensions, mother’s BMI, level of
prenatal care, and history of poor birth outcomes. In addition to this we also had detailed
information regarding the antidepressants prescribed which helped us control for duration
and trimester of exposure.
5.4.4. Observational Studies/Establishing a Causal Relationship
All the studies conducted to examine the association between prenatal exposure to
antidepressants and risk of adverse birth outcomes have been observational. Several
standard methods have been used in this setting to estimate the association between
prenatal exposure to antidepressants and the risk of adverse birth outcomes. However,
none of the methods can be used to establish causality. Ideally a randomized controlled
trial would be conducted to establish a causal association. Due to ethical concerns we
cannot randomize treatment in this study population. Hence we used marginal structural
models, a relatively new technique that has not been used in the field of reproductive
epidemiology63-64. In MSM, we used counterfactuals to create a pseudo population that is
similar to our actual study population62. Using this pseudo population we were able to
statistically mimic a randomized control trial62-66.
The result from the two analysis were in the same direction; both logistic
regression and marginal structural models estimated an increase in the risk of adverse
birth outcomes. When conducting analysis using logistic regression the odds of having

113

preterm delivery were 1.58 (95%CI: 1.19 – 2.10) times higher in the study participants
that received an antidepressant during pregnancy as compared to those who did not
receive any antidepressants at any time during the pregnancy. Whereas, according to the
analysis conducted using marginal structural models, the odds of preterm delivery were
1.72 times (95% CI: 1.63 – 1.79) in the group that received antidepressants during
pregnancy as compared to the group that did not receive an antidepressant during
pregnancy. Similar results were observed for low birth weight/small for gestational age
and prevalence of NICU admissions. Using logistic regression it was estimated that
antidepressant use during pregnancy was associated with higher odds of the infant having
low birth weight/being small for gestational age, OR = 1.57 (95% CI: 1.42 – 2.76) and/or
NICU admissions, OR: 1.45 (95%CI 1.28 – 2.26). Marginal structural models showed
that the prenatal exposure to antidepressants increased the odd of having low birth
weight/small for gestational age 1.63 times (95%CI: 1.53 – 1.73) and the odds of having
a NICU admission by 1.66 times (95% CI: 1.58 – 1.73).
Marginal structural models gives a stronger association. This is possibly due to
the fact that they control for maternal depression more effectively providing with the
effect of antidepressants alone on the risk of adverse birth outcomes. Also, marginal
structural models provide us tighter confidence intervals. Marginal structural models and
logistic regression both suggest that prenatal exposure to antidepressants is associated
with an increased risk of adverse birth outcomes. The weights used in marginal structural
models can be interpreted as the number of copies of each observation that are necessary
to form a pseudo-population in which use antidepressants is confounded. Hence, the
results are more robust with narrower confidence intervals.
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5.5 CONCLUSION
In our study we examined the impact of prenatal exposure to antidepressants on
adverse birth outcomes such as preterm delivery, low birth weight/small for gestational
age and NICU Admissions. We conducted the analysis using two different statistical
techniques. First logistic regression, as this is the most commonly used technique and
would help us make our results more comparable. Second, we used marginal structural
models, a relatively new method which helped us delineate the effect of antidepressants
from the effect of depression. Marginal structural models also helped us to mimic a
randomized control trial statistically which cannot be conducted practically in this
scenario. Using both analyses we found that prenatal exposure to antidepressant is
significantly associated with an increase in the odds of having adverse birth outcomes
such as preterm delivery, low birth weight/small for gestational age, and NICU
admissions. The odds ratio ranged from 1.58-1.99 and were all statistically significant.
Further we did a comparative analysis between the different types of antidepressants
using SSRIs as the reference group. We found that all antidepressants are associated with
the risk of adverse birth outcome, there is no difference in the measure of risk among the
various classes of antidepressants compared to the referent category, SSRI. We also
found that the duration and trimester of exposure to antidepressant did not significantly
impact the risk of adverse birth outcomes.
We addressed some of the key concerns in the existing literature through our
study. We not only controlled for maternal depression which is an important confounder
but we were also able to control for confounders such as maternal smoking, maternal
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BMI, parity, risk of previous adverse birth outcomes etc. We also did an analysis to
compare the relative risk of the class of antidepressants on the risk of adverse birth
outcome by using SSRIs as the referent group. This analysis gave more insight into the
other classes of antidepressants and also attempted to establish their relative safety. We
used to separate analytical tools for this study. We used the traditional logistic regression
to ensure that our study is comparable to other studies in the current literature. We also
used the relatively new marginal structural models to statistically mimic a randomized
controlled trial from observational data. In conclusion we found that prenatal exposure to
antidepressants is significantly associated with a higher risk of adverse birth outcomes
such as preterm delivery, low birth weight/small for gestational age, and NICU
admissions, irrespective of the type of antidepressant prescribed and duration and
trimester of exposure.
5.5.1 Strengths
The strengths of our study are:
1. This study was conducted using a merged dataset from South Carolina Medicaid
and South Carolina Registry of Births which is a database of all birth certificates
issued in the state of South Carolina. This provided us a rich data which captured
a number of important confounders such as prenatal care, mother’s education,
mother’s weight, uterine bleeding etc. as well as risk factors such as maternal
smoking, alcohol use, gestational diabetes, gestational hypertension etc.
2. The merged dataset also allowed us to control for behavioral confounders such
as, maternal smoking, maternal alcohol use, maternal race, maternal and paternal
occupation, conditions during the pregnancy (ex. gestational hypertension,
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anemia, eclampsia, gestational diabetes, uterine bleeding), birth abnormalities or
anomalies (ex. cleft palate, heart malformations), multiple births, etc. Data from
the birth certificates gave us information regarding the birth outcomes such as
pre-term delivery, low birth weight/small for gestational age, and NICU
admissions which helped us identify the cases accurately.
3. This study has attempted to explore the causal association between prenatal
exposure to antidepressants and risk of adverse birth outcomes using MSM within
an observational data set.
4. The South Carolina Medicaid finances about 50% of total births in state. This
gave us a large enough sample size to facilitate detailed subgroup analysis and
confidently extrapolate our findings to this population results.
5. South Carolina Medicaid has a strong representation of vulnerable populations
including racial/ethnic minorities generally representative of the state population.
Race and ethnicity are recorded in this database, in contrast to many commercial
databases. The South Carolina Medicaid population is relatively homogeneous
with respect to the socio-economic status.
6. South Carolina Medicaid Claims database can be merged with the birth
certificates which contained information on confounders such as mother’s BMI,
parity, smoking status etc. Maternal obesity, smoking during pregnancy and parity
have been found to significantly associate with the risk of adverse birth outcomes.
Having information on these confounders allowed us to control for them in our
analysis.
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5.5.2 Limitations
Some of the limitations of our study are:
1. The study was conducted using the South Carolina Medicaid database which
limits generalizability for the results to other states.
2. Depression is often associated with other psychiatric illnesses, in this study we
did not control for other psychiatric disorders or prescription of antipsychotic
medicines.
3. Only the month and year of delivery/birth date was given in the Medicaid
database hence for the ease analysis we used the 15 of each month as the date. As
a result the date of conception and trimester dates might not be accurate.
4. There is a potential of considerable misclassification arising from the use of low
birth weight as an outcome. Low birth weight is associated with preterm birth, so
the magnitude and direction of misclassification will differ by preterm and full
term birth. Also, small for gestational age may not be a perfect measure for
intrauterine growth. As the estimated gestational age might not be accurate.
5. Since this is an observational study, we cannot draw a causal inference of
association. Although MSM helps statistically mimic a randomized control trial,
there might be some unobserved confounders that we could not control for.
6. The causal inference from our MSM depends on two key assumptions
a. We assumed that the covariates in maternal depression are sufficient to
adjust for both confounding and selection bias due to loss to follow-up.
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b. We assumed that our MSM for the effect of antidepressants on adverse
birth outcomes is correctly specified. In an observational study, these
assumptions cannot be tested.
5.5.3. Future Research Recommendations
Current research shows that antidepressant use in pregnancy is well studied and
gives sufficient evidence to state that the treatment of pregnant women with
antidepressants is a challenging and complex task for the healthcare providers. In our
study we have tried to establish a causal association between prenatal exposure to
antidepressants and adverse birth outcomes, further research in the field is needed.
Studies have not yet adequately controlled for factors that can adversely affect pregnancy
and birth outcomes, such as other maternal illness or adverse health behaviors (e.g.,
alcohol consumption, recreational drugs, etc.). Hence there is a need for more focused
studies that take into account these important factors, as they may influence the
association between antidepressant exposure and adverse birth outcomes. There is a need
to study the duration of exposure with more precision, while taking into account the
patient’s adherence to the prescribed medications. Also there is a need to examine and
clarify a dose response relationship between the prenatal exposure to antidepressants and
risk of adverse birth outcomes, if such a relationship exists This would help clinicians
know the threshold dose they can use to treat cases that absolutely require
pharmacotherapy to control depression. Another recommendation would be to include
more recently approved antidepressants. Lastly, there is a need for a more inclusive
definition of exposure which measure the dose, duration, trimester of exposure, and the
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gaps in therapy. Such a definition would allow a more comprehensive measure of the
construct, resulting in more precise results and conclusions.
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APPENDIX A: CORRELATION MATRIX OF THE VARIABLES INCLUDED IN THE ANALYSIS
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Table A1 Correlation Matrix of the Variables Included in the Analysis
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